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Abstract 
Sepsis is defined as a documented infection with systemic inflammatory response 
syndrome (SIRS). When pathogens have been detected by blood culturing method, the 
condition is classified as a bloodstream infection (BSI). The frequency of severe sepsis is 
approximately 90.4 cases per 100 000 population in Europe and circa 751 000 cases 
annually in United States. Sepsis is associated with high mortality rates ranging up to 50 
% in most severe cases. The presence of immunocompromising conditions, chronic 
diseases, prosthetic devices such as intravenous lines or urinary catheters and higher age 
are factors which typically increase the infection risk. Currently, common causative 
bacteria such as Staphylococcus aureus, other staphylococci, Escherichia coli and 
Klebsiella pneumoniae are detected using blood culturing method. It is time-consuming, 
especially in case of fastidious and slow growing bacteria and thus initial empirical 
therapy typically contains broad-spectrum antimicrobial(s). 
  
Rapid methods for sepsis/BSI diagnostics are needed to improve patient outcomes, 
decrease length of stay in hospital and related costs. When causative pathogens are 
identified earlier, also appropriate antimicrobials can be administered earlier. The aim of 
this study was to develop a polymerase chain reaction (PCR) and microarray-based assay 
for the detection of main causative pathogens and methicillin resistance marker from 
patients with suspected sepsis/BSI. The assay, which utilized the Prove-it™ TubeArray 
platform, was first developed for detection of 12 bacterial species, coagulase negative 
Staphylococcus group and methicillin resistance marker. The performance of this assay 
was evaluated with blood culture samples. The bacterial panel was further improved for 
the detection of over 50 causative pathogens in sepsis/BSI. This optimized assay was 
clinically validated with over 3300 blood culture samples collected from HUSLAB, 
Finland and UCLH, United Kingdom. The developed assay, named Prove-it™ Sepsis, 
demonstrated 94.7 % sensitivity and 98.8 % specificity. Based on this validation study, the 
assay was CE-marked for in vitro diagnostics in Europe. This diagnostics assay with the 
improved target panel was also successfully transferred and optimized to the Prove-it™ 
StripArray platform, whose capacity of 1-96 simultaneous analyses responds to the need 
of hospital laboratories dealing with larger sample amounts. 
 
Another aim of this study was to evaluate the PCR and microarray assay’s suitability for 
identification of pathogens directly from whole blood samples without a culturing step. 
The assay was combined with a selective bacterial deoxyribonucleic acid (DNA) isolation 
method and the performance of this combination was evaluated with spiked blood 
samples. Detection limit of 11-600 colony forming units per mL was obtained depending 
on the target organism. In addition, analytical sensitivity of 1-21 genome equivalents for 
the PCR and microarray assay was demonstrated. These results showed proof-of-concept 
for the combination assay and feasibility of the PCR and microarray assay to be used for 
more sensitive applications after an extensive optimization phase. 
 
  
 
 
Molecular assays have opened a new era in microbiological laboratories and brought a 
broadened perspective parallel to the conventional culturing and phenotype-based method. 
Also in this study, genotype-based characterization was utilized to offer more accurate 
identification than conventional culturing. In future, understanding the clinical relevance 
of DNAemia may open new strategies to the management of septic patients using nucleic 
acids-based assays. 
  
 
 
Tiivistelmä 
Sepsis tarkoittaa vakavaa yleisinfektiota ja tulehdusreaktio-oireyhtymää, johon liitetään 
usein veriviljelypositiivisuus. Yleisyys Euroopassa on 90.4 tapausta 100 000 ihmistä 
kohden ja Yhdysvalloissa noin 751 000 tapausta vuosittain. Sepsikseen liitetään korkea 
kuolleisuus, jopa 50 %. Heikentynyt immuunipuolustus, krooniset sairaudet sekä korkea 
ikä saattavat lisätä sairastumisriskiä. Yleisimpiä aiheuttajabakteereita ovat muun muassa 
Staphylococcus aureus ja muut stafylokokit, Escherichia coli ja Klebsiella pneumoniae. 
Resistentit ja multi-resistentit bakteerikannat ovat yleensä hoidollisesti vaikeimpia, koska 
tehokkaan mikrobilääkehoidon kohdistaminen saattaa olla vaikeaa. Tällä hetkellä sepsis 
osoitetaan veriviljelydiagnostiikan avulla, jolloin mikrobi pyritään tunnistamaan potilaan 
verestä. Viljely on hidas menetelmä vaativissa kasvuolosuhteissa kasvavien mikrobien 
kohdalla, siksi potilaan empiirinen ensihoito koostuu yleensä laajakirjoisesta 
mikrobilääkkeestä tai lääkeyhdistelmistä.  
 
Nopeutetun diagnostiikan avulla mikrobi(t) pystyttäisiin tunnistamaan nopeammin ja näin 
ollen kohdistettu lääkehoito aloittamaan aikaisemmin. Tämän työn tavoitteena oli kehittää 
PCR-monistus- ja mikrosirutekniikkaan perustuva testi sepsiksen aiheuttajamikrobien 
tunnistamiseen. Ensin kehitettiin tunnistus 12 bakteerilajille, koagulaasinegatiiviselle 
stafylokki-ryhmälle sekä metisilliiniresistenssi-geenimarkkerille positiivisesta 
veriviljelynäytteestä. Testialustaksi optimoitiin Prove-it™ TubeArray -mikrosiru, jolla 
pystyi analysoimaan 1-24 näytettä kerrallaan. Testin toimivuus arvioitiin kerätyillä 
veriviljelynäytteillä. Seuraavassa vaiheessa mikrobipaneeli laajennettiin kattamaan yli 50 
sepsiksen aiheuttajamikrobia. Tämän parannetun testiversion toimivuus arvioitiin yli 3300 
veriviljelynäytteen avulla, jotka oli kerätty HUSLAB:ssa Suomessa ja UCHL:ssä Isossa-
Britaniassa. PCR- ja mikrosirutesti nimettiin Prove-it™ Sepsis -testiksi, jolle määritettiin 
94.7 %:n herkkyys ja 98.8 %:n tarkkuus, kun testitulosta verrattiin veriviljelyn 
mikrobilöydöksiin. Tämän arvioinnin perusteella testi CE-merkittiin in vitro 
diagnostiikkaan Euroopassa. Kehitystä jatkettiin Prove-it™ TubeArray -testialustan lisäksi 
myös Prove-it™ StripArray -testialustalle, jolla saattoi analysoida 1-96 näytettä 
samanaikaisesti. Useamman näytteen yhtäaikainen analysointi vastaa paremmin tarvetta 
isoissa laboratorioissa, joissa näytekapasiteetti on suurempi. 
 
Lisäksi tutkittiin PCR- ja mikrosirutestin soveltuvuutta mikrobitunnistukseen suoraan 
potilaan verinäytteestä ilman rikastusvaihetta. Spesifinen bakteeri-DNA:n 
eristysmenetelmä potilasverinäytteestä yhdistettiin PCR- ja mikrosirutestin kanssa. Tätä 
yhdistelmää arvioitiin verinäytteillä, joihin oli lisätty tietty pitoisuus bakteereita. 
Analysoinnin tuloksena tämän yhdistelmätestin herkkyydeksi määritettiin bakteerilajista 
riippuen 11-600 pesäkettä muodostavaa yksikköä per mL. Lisäksi PCR- ja mikrosirutestin 
analyyttiseksi herkkyydeksi määritettiin 1-21 genomiekvivalenttia. Tulokset osoittivat, 
että PCR- ja mikrosirutesti saattaisi olla kehitettävissä myös herkempiin sovelluksiin kuin 
rikastettuun näytemateriaaliin, esimerkiksi muokkaamalla testiä yhdessä kuvatun DNA-
eristysmenetelmän kanssa.   
 
  
 
 
Molekyylipohjaiset testit ovat jo avanneet uuden aikakauden mikrobiologisissa 
laboratorioissa. Mikrobien geenipohjainen luokittelu ja karakterisointi tarjoavat sellaisia 
mahdollisuuksia, joita fenotyyppipohjaisella luokittelulla ei pystytä välttämättä 
saavuttamaan. Näitä havaintoja tehtiin myös tässä tutkimuksessa, kun PCR- ja 
mikrosirutesti tunnisti bakteereja potilasnäytteistä, joissa viljely epäonnistui tai ei antanut 
oikeaa tulosta. Sepsispotilaan verenkierrosta löytyvän bakteeri-DNA:n kliininen 
merkittävyys infektioissa ei ole vielä täysin selvää. Sen ymmärtämisen myötä voidaan 
kehittää nopeampia nukleiinihappopohjaisia strategioita sepsispotilaan diagnosointiin. 
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1 Introduction 
1.1 Sepsis 
1.1.1 Definition 
The definitions of sepsis, severe sepsis and septic shock were introduced in the consensus 
conference of American College of Chest Physicians (ACCP) and Society of Critical Care 
Medicine (SCCM) at the beginning of the 90s (Bone et al., 1992). Earlier terms like 
septicemia, bacteremia and sepsis syndrome were used without precise definitions to 
characterize patients with severe generalized infection. According to the consensus 
conference, sepsis is defined as a documented infection with systemic inflammatory 
response syndrome (SIRS) (Bone et al., 1992). Definitions were revised in 2001, but were 
left practically unchanged. The expanded list of diagnostic criteria for sepsis, including a 
list of variables related to the general, inflammatory, hemodynamic, organ dysfunction 
and tissue perfusion symptoms were prepared to help recognition of sepsis, but none of 
those were specific for sepsis (Levy et al., 2003). Sepsis is defined severe when 
associated to organ dysfunction, hypoperfusion or hypotension. Manifestations of 
hypoperfusion may include, but are not limited to, lactic acidosis, oliguria or an acute 
alteration in mental status. The most complicated condition is septic shock, which is 
defined as the presence of sepsis and refractory hypotension, i.e. systolic blood pressure 
less than 90 mmHg, mean arterial pressure less than 65 mmHg or a decrease of 40 mmHg 
in systolic blood pressure compared to baseline unresponsive to a crystalloid fluid 
challenge of 20 to 40 mL / kg (Bone et al., 1992; Levy et al., 2003; Annane et al., 2005). 
Definitions of common sepsis-related terms are shortly summarized in Table 1. 
 
Consensus conference defined also the term bacteremia, which is the presence of viable 
bacteria in the blood (Bone et al., 1992). When pathogens have been detected from blood 
culture and clinical symptoms of systemic infection have been obtained, the condition is 
called a bloodstream infection (BSI). BSIs can be further divided to primary and 
secondary infections. Shortly, infection is a primary BSI if the pathogen identified from 
one or more blood culture samples is not related to an infection at another site. Primary 
infection is often associated with intravascular catheters. Infection is secondary BSI if the 
pathogen cultured from blood is related to an infection with the same pathogen at another 
site (Paolucci et al., 2010; Juan-Torres and Harbarth, 2007).  
 
According to the definition, detection of sepsis does not require detection of BSI. A high 
portion of blood cultures are negative although the majority of patients have sepsis related 
symptoms such as fever, hypotension or oliguria. Several reasons, such as pathogen-
produced pyrogenic agents, may cause clinical signs of sepsis with negative blood 
culture. This condition is called clinical sepsis. Characterization of clinical sepsis may be 
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difficult since the patient’s condition may not be unambiguous and only one of the main 
signs (fever, hypotension, or oliguria) is required together with other criteria (Garner et 
al., 1988; Hugonnet et al., 2004; Soraya et al., 2008).  
 
Table 1. Definitions of sepsis-related terms. 
Terms Definition 
Bacteremia Presence of viable bacteria in blood. 
Bloodstream 
infection 
(BSI) 
Presence of clinical symptoms of systemic infection and positive 
blood culture results. 
Systemic 
imflammatory 
response 
syndrome 
(SIRS) 
Presence of two or more of the following: 
 - Body temperature > 38 °C or < 36  °C 
 - Heart rate  > 90 beats per min 
 - Respiratory rate > 20 breaths per minute or arterial CO2 tension                   
   < 32 mm Hg or need for mechanical ventilation 
 - White blood cell count > 12 000/mm
3 
or < 4000/mm
3 
or immature  
   forms > 10 % 
Sepsis 
The systemic response to a documented infection together with SIRS 
criteria. 
Severe sepsis 
Presence of sepsis associated with organ dysfunction, hypoperfusion, 
or hypotension. The manifestations of hypoperfusion may include, 
but are not limited to, lactic acidosis, oliguria, or an acute alteration 
in mental status. 
Septic shock 
Presence of sepsis with hypotension despite adequate fluid 
resuscitation. It includes perfusion abnormalities such as lactic 
acidosis, oliguria, or an acute alteration in mental status.  
Clinical 
sepsis 
Presence of either fever, hypotension, or oliguria, and all of the 
following: 
 - Blood not cultured or no microorganism isolated 
 - No apparent infection at another site 
 - Appropriate antimicrobial therapy for sepsis have been directed 
(References: Bone et al., 1992; Levy et al., 2003; Annane et al., 2005; Garner et al., 
1988). 
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1.1.2 Incidence and costs 
Estimation of incidence of severe sepsis is around 18 million cases worldwide annually 
and circa 1400 patients die from severe sepsis each day (Angus et al., 2001; Bone et al., 
1992 Daniels et al., 2011). In the United States (US), sepsis is defined to be the 10th 
leading cause of death and septic shock to be the first cause of death in intensive care 
units (ICU) (Minino et al., 2007). Approximately 751 000 cases of severe sepsis occur 
annually in the US and an average length of stay in hospital for a patient with severe 
sepsis is 19.6 days with an associated cost of $22 100. Treatment of these patients 
involves an economic cost estimated at $16.7 billion annually (Angus et al., 2001). In the 
European Union (EU), the frequency of severe sepsis is estimated to be 90.4 cases per 
100 000 population and the management of patients with severe sepsis bear around €7.6 
billion healthcare costs per year in Europe (Daniels, 2011). 
 
High mortality rates are associated with sepsis and BSI. Angus and co-workers (2001) 
demonstrated that the mortality rate of patients with severe sepsis was 28.6 % in the US. 
Age has a strong influence on the incidence of severe sepsis and mortality increased from 
10 % to 38.4 % when pediatric patients were compared to a group of > 85 year age 
patients. Similar values were also obtained in Europe in the Sepsis Occurrence in Acute 
Ill Patient (SOAP) study. The mortality rates in the ICU were 27 % for patients with 
sepsis, 32 % for patients with severe sepsis and 54 % for patients with septic shock 
(Vincent et al., 2006). 
 
1.1.3 Infection sites and etiology 
Sepsis is associated with community- or hospital-acquired infections, and the 
classification is typically difficult. Several seemingly harmless conditions may cause 
sepsis, but often it is caused by a more serious medical primary infection, such as 
pneumonia or meningitis. The presence of immunocompromising conditions, chronic 
diseases, prosthetic devices such as intravenous lines or urinary catheters and higher age 
are factors which typically increase the infection risk (Nguyen et al., 2006). The most 
frequent causes of infections in septic patients are pneumonia, bloodstream infections 
(including infective endocarditis), intravascular catheter-related sepsis, intra-abdominal 
infections, urosepsis and surgical wound infections (Harbarth et al., 2003; Calandra and 
Cohen, 2005). Many studies have also described the same typical infection sites like lung 
(50 - 68 % of the patients), abdomen (20 - 25 % of the patients), urinary tract (7 - 14 % of 
the patients), wounds and blood (Ebrahim, 2011; Vincent et al., 2006; Vincent et al., 
2011). 
 
Different microbes can cause sepsis, such as bacteria, fungi and viruses, but diagnosis of 
bacterial and fungal sepsis is the most studied. Therefore, the present study focused only 
on bacterial sepsis diagnostics. Both Gram-positive and Gram-negative bacteria cause 
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sepsis-related infections. Vincent and co-workers (2006) reported the distribution of 
bacteria in their European SOAP study of 3147 patients with the median age of 64 years. 
Gram-positive bacteria were identified in 40 % of the positive samples, Gram-negative 
bacteria in 38 % of the positive samples and fungi in 17 % of the positive samples 
(Vincent et al., 2006). In another study concerning neonatal sepsis cases in Nepal, the 
distribution was 44.1 % of Gram-positive and 55.9 % of Gram-negative bacteria (Gyawali 
and Sanjana, 2012). According to several studies, the most common Gram-positive 
bacteria detected from blood cultures are Staphylococcus aureus, coagulase negative 
Staphylococcus (CNS) (including Staphylococcus epidermidis), Streptococcus 
pneumoniae and other streptococci. Common Gram-negative bacteria are Escherichia 
coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus spp. and other 
members of Enterobacteriaceae group (Vincent et al., 2006; Beekmann et al., 2003; 
Reimer et al., 1997; Harbarth et al., 2003; Nguyen et al., 2006). In addition, especially 
among neonates Haemophilus influenzae and Neisseria meningitidis are common findings 
in infections (Nizet and Klein, 2011). 
 
It is estimated that S. aureus, E. coli and other members of the Enterobacteriaceae group, 
P. aeruginosa, S. pneumoniae and Candida albicans represent typically true causative 
pathogens in infections when detected from blood culture. Pathogens such as CNS, 
Corynebacterium spp., Bacillus spp. and Propionibacterium acnes are often classified as 
contaminations when detected from blood culture. Contaminations are typically 
originated from skin (Reimer et al., 1997, Hall and Lyman, 2006). However, studies have 
shown the clinical importance of also these bacteria as causative agents in infections and 
the interpretation of these bacterial findings needs to be investigated carefully (Otsuka et 
al., 2005; Adler et al., 2005; Park et al., 2011).  
 
1.1.4 Antimicrobial resistances and MRSA 
The number of infections caused by bacteria resistant to one or more of the current 
antimicrobials has been estimated to increase. The well-studied antimicrobial resistances 
are methicillin (among S. aureus and other Staphylococcus ssp.) and vancomycin (among 
e.g. Enterococcus ssp.) resistances. In addition, bacteria including Enterobacteriaceae 
group and generating resistances by producing extended spectrum β-lactamase, metallo-β-
lactamase or carbapenemase enzymes are under extensive investigation (Bhattacharya, 
2013). Bacterial resistances have a major influence on the outcome of septic patients and 
it has been assessed that the presence of bacterial resistance approximately doubles the 
mortality rate associated with sepsis (Turnidge, 2003). A highly resistant group of 
bacteria which is related to worse patient outcomes is named the ESKAPE group. 
Pathogens included in this group are Enterococcus faecium, S. aureus, K. pneumoniae, 
Acinetobacter baumannii, P. aeruginosa and Enterobacter species (Boucher et al., 2009; 
Rice, 2008). In addition, methicillin-resistant S. aureus (MRSA), P. aeruginosa, A. 
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baumannii, and Stenotrophomonas maltophilia constitute another group typically 
classified as highly multi-resistant bacteria and difficult to treat (Trouillet et al., 1998).  
 
Methicillin-resistant S. aureus is the one of the most known and studied resistant bacterial 
species causing high mortality and associated often with inadequate antimicrobial 
treatment (Lodise et al., 2003). According to a large European sepsis study, blood 
cultures were positive in 60 % of the patients with sepsis and MRSA was detected in 14 
% of those samples (Vincent et al., 2006). Another study related to BSI showed that S. 
aureus was the causative agent in 24 % of the samples and 31 % of those were resistant to 
methicillin (Latif et al., 2009). S. aureus is the second most common pathogen causing 
BSIs and the most common causative pathogen in nosocomial BSIs. Shorr and co-
workers (2006) reported that S. aureus was the causative agent in 25.7 % of healthcare-
associated BSIs (HCA-BSI), in 29.7 % of nosocomial BSIs and in 17.8 % of community 
acquired BSIs (CA-BSI) in the US. The prevalence of MRSA in these groups was 41 %, 
52 % and 26 %, respectively. Around 25 % of healthy humans are colonized with S. 
aureus and 1.5 - 3 % with MRSA. It has been estimated that in over 80 % of people who 
have S. aureus BSI, the same isolate can also be isolated from their nares (del Rio et al., 
2009).  
     
Methicillin resistance in Staphylococcus species is associated with the additional 
penicillin binding protein PBP2a, which has low affinity for all β-lactam antimicrobials. 
PBP’s role as a transpeptidase is to catalyze the formation of cross-bridges in bacterial 
cell wall peptidoglycan.  Semisynthetic penicillin such as methicillin, nafcillin and 
oxacillin has been designed for the treatment of infections caused by beta-lactamase-
producing staphylococci. Typically these β-lactam antimicrobials bind to the methicillin-
sensitive S. aureus (MSSA) native PBPs disrupting the synthesis of peptidoglycan cell 
wall and resulting in bacterial death. PBP2a has low affinity for all β-lactam 
antimicrobials which leads to no disruption in cell wall peptidoglycan synthesis and 
resulting in normal bacterial growth (Berger-Bachi and Rohrer, 2002; Hanssen and 
Ericson Sollid, 2006; IWG-SCC, 2009). The highly mobile element of Staphylococcus 
species, the staphylococcal cassette chromosome SCCmec, carries the mecA gene which 
encodes PBP2a. SCCmec elements are classified based on their putative cassette 
chromosome recombinase genes (ccr) and overall genetic composition. Currently, at least 
11 types of SCCmec (types I-XI) elements and several variants have been reported based 
on differences in their structure and size (Peng et al., 2010; Shore et al., 2011). SCCmec 
types I-III are usually related to hospital-acquired MRSA (HA-MRSA) and types IV and 
V to community-acquired MRSA (CA-MRSA) (Berglund and Söderquist, 2008). 
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1.1.5 Administration of appropriate antimicrobial therapy 
According to the Surviving Sepsis Campaign recommendation, intravenous antimicrobial 
therapy should start within the first hour of recognition of severe sepsis or septic shock 
and the empirical therapy should contain one or more antimicrobials (Dellinger et al., 
2008). Combination therapy is supposed to cover the spectrum of all possible pathogens. 
In case of multi-microbial infections or resistant bacteria, targeted selection of 
antimicrobials leads to better patient outcomes (Nguyen et al., 2006).  Combination 
therapy should not be administered longer than 3-5 days and antimicrobial therapy should 
be revised daily to avoid the development of resistance and to reduce toxicity and costs. 
When the causative agent and susceptibility profile has been defined, narrowed 
antimicrobial treatment should be used. There is no evidence that combination therapy 
would give better response than directed mono-therapy if the causative agent has been 
identified. The suitable duration of the therapy is typically 7–10 days (Dellinger et al., 
2008; Nguyen et al., 2006).  
 
Delayed antimicrobial treatment in patients with severe sepsis or septic shock is known to 
increase mortality. Inappropriate therapies are often related to the pathogen resistances, 
such as MRSA, which were noted also in the recommendations of Surviving Sepsis 
Campaign (Dellinger et al., 2008).  One study showed that almost 1/3 of patients received 
inappropriate antimicrobial treatment and in most of those cases the causative agent was 
either vancomycin-resistant Enterococcus, CNS, P. aeruginosa or C. albicans (Ibrahim et 
al., 2000). In another study, inappropriate therapy was associated mainly with multi-
resistant bacteria such as P. aeruginosa, S. maltophilia, Acinetobacter spp. and MRSA 
(Harbarth et al., 2003). It has been demonstrated that every additional hour without 
appropriate antimicrobial treatment increases the risk for death in septic patients by 7.6 % 
during the first six hours from hypotension onset (Kumar et al., 2006). Harbarth and co-
workers (2003) compared 28-day mortality between initially an appropriately treated 
group and an inappropriately treated group. The mortality rates were 24 % and 39 %, 
respectively. Similarly, another study demonstrated mortality rates in Gram-negative 
bacteremia to be 18 % for the group of appropriately treated and 34 % for the group of 
inappropriately treated patients (Bochud et al., 2004). In addition to the mortality rate, the 
administration of ineffective therapy correlated also to the length of stay in hospital 
increasing the related costs. High mortality rate and costs cause pressure to develop faster 
methods for the identification of causative agents giving guidance to the appropriate 
antimicrobial therapy earlier (Carrigan et al., 2004; Harbarth et al., 2003; Beekman et al., 
2003).  
 
Detection of sepsis is often difficult and therefore adequate treatment may be delayed. 
Attempts to improve the situation have included finding specific markers indicating the 
patient’s condition and helping in the diagnosis. Several biomarkers for sepsis are under 
investigation. These may provide information suitable for diagnostics, monitoring and 
therapeutic decision making (Lever and Mackenzie, 2007). Probably the most 
investigated diagnostic biomarkers, which could indicate the presence or absence of a 
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disease state or other clinical condition, are C-reactive protein (CRP) and procalcitonin. 
CRP is a hepatocyte- produced acute-phase reactant found in the blood, which amount is 
increasing within 4–6 hours of an inflammatory stimulus. Procalcitonin (PCT) is a 
precursor for the hormone calcitonin and the level of PCT has been found to increase in 
children with sepsis and bacterial infection. As a monitoring biomarker, the level of PCT 
is decreasing quickly when appropriate antimicrobial therapy is initiated. In addition, 
there are also other biomarkers under investigations, such as CD64, IL-18 and lactate. 
Clinicians may recognize patient condition faster by screening biomarkers. However, the 
role of these biomarkers is still under investigation (Standage and Wong, 2011; Lever and 
Mackenzie, 2007; Schuetz et al., 2011).  
 
1.2 Diagnosis of pathogens causing sepsis and BSI  
Conventional blood culture including pathogen subculturing on appropriate media and 
antimicrobial susceptibility evaluation are the gold standard methods for identification of 
sepsis and BSI causing pathogens. Phenotype-based characterization such as staining as 
well as microscopy and testing biochemical properties of pathogens are described as 
traditional microbiological methods in diagnostic laboratories. In order to respond to the 
need for more rapid diagnostics, new assays with various detection strategies have been 
developed. One novel approach is to use mass spectrometry for characterization of 
pathogens based on their proteomic profile. Another strategy is to use nucleic acids (NA) 
for identification of pathogens from clinical samples. NA-based assays are typically 
classified as hybridization- or amplification-based assays depending on the used 
technique. In addition, NA-based mass spectrometry applications have also been 
developed (Mancini et al., 2010; Weile and Kanbbe, 2009; Peters et al., 2004). 
 
The sample type for these new assays is either positive blood culture or patient blood. In 
some assays, clinical sample cannot be used as such and thus, an additional culturing step 
on appropriate agar media from the original sample is required before the final analysis. 
Recent developments show a trend to provide identification of Gram-positive and Gram-
negative bacteria, fungi and resistance markers in the same assay or simultaneous 
identification with several parallel reactions. However, the coverage of the target panel is 
linked to the used technique and varies between assays (Afshari et al., 2012; Weile and 
Kanbbe, 2009; Mancini et al., 2010). Table 2 summarises examples of well-established 
assays and techniques used in sepsis diagnostics (some also in BSI diagnostics). 
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Table 2. Examples of commercially available systems and assays used in sepsis 
diagnostics (some also in BSI diagnostics). 
Method description Sample type Assay (Manufacturer) 
Blood culturing (automated systems)   
Blood culturing automates, 
where increasing levels of CO2 
or headspace gas pressure are 
continuously monitored with 
fluorometric or colorimetric 
sensors, indicating growth of 
pathogens in the culture media. 
Whole blood 
BACTEC™ FX/9000 series                          
(Becton Dickinson, USA) 
Whole blood 
BacT/ALERT series                           
(bioMérieux, France) 
Whole blood  
VersaTREK                                                      
(Thermo Fisher Scientific, 
USA)  
Phenotypic-based characterization (automated systems) 
Pathogen identification from 
pure bacterial/fungal culture by 
screening biochemical 
properties, including 
antimicrobial susceptibility 
evaluation. 
 Pure bacterial/fungal 
culture from positive 
blood culture   
VITEK
®
 (BioMérieux, 
France) 
 Pure bacterial/fungal 
culture from positive 
blood culture   
BD Phoenix™ (Becton 
Dickinson, USA)  
 Pure bacterial/fungal 
culture from positive 
blood culture   
Microscan WalkAway
®
                                                    
(Siemens Healthcare 
Diagnostics, Germany)  
Protein-based characterization (automated systems)   
Pathogen identification from 
pure bacterial/fungal culture by 
screening of proteins with 
matrix-assisted laser desorption 
ionization-time of flight mass 
spectrometry                
(MALDI-TOF MS).  
 Pure bacterial/fungal 
culture from positive 
blood culture    
Flex™ MALDI-TOF series                                                                       
(Bruker, Germany)   
 Pure bacterial/fungal 
culture from positive 
blood culture    
VITEK
®
 MS (BioMérieux, 
France) 
 Pure bacterial/fungal 
culture from positive 
blood culture    
AXIMA (Shimadzu 
Corporation, Japan) 
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Nucleic acid- and hybridization-based assays   
Pathogen identification by 
fluorescent in situ 
hybridization (FISH)-based 
technology, where 
fluorescently labeled probes 
are hybridized to conserved 
rRNA sequences.  
Positive blood 
culture 
PNA-FISH (AdvanDX, USA) 
Positive blood 
culture 
HemoFISH assays (miacom, 
Germany)  
Pathogen identification by 
hybridization protection assay 
(HPA) technology and 
analysis with Hologic Gen-
Probe's luminometers. 
Positive blood 
culture 
AccuProbe (Gen-Probe Inc, 
USA)  
Pathogen identification based 
on oligonucleotides attached 
to gold nanoparticles followed 
by hybridization on 
microarray. 
Positive blood 
culture 
Verigene
®
 assay (Nanosphere 
Inc, USA)  
Nucleic acid- and amplification-based assays   
Pathogen identification by 
multiplex real-time PCR 
assay. 
Whole blood  
LightCycler
®
 SeptiFast Test 
MGRADE (F. Hoffmann-La 
Roche, Germany)  
Whole blood  MagicPlex (SeeGene, Korea)  
Positive blood 
culture 
Gene Xpert MRSA/MSSA 
assay (Cepheid, USA)  
Pathogen identification by 
multiplex PCR followed by 
gel electrophoresis analysis. 
Whole blood  VYOO
®
 (Sirs-Lab, Germany)  
Pathogen identification by 
broad-range PCR followed by 
sequencing analysis. 
Whole blood  
SepsiTest
®
 (Molzym GmbH & 
Co., Germany)  
Pathogen identification by 
multiplex PCR followed by 
electrospray ionization mass 
spectrometry (ESI-MS) 
analysis. 
Whole blood and 
positive blood 
culture 
PLEX-ID (Abbott Ibis 
Bioscience, USA)  
(References: www.bd.com; www.biomerieux.com; www.trekds.com; 
www.medical.siemens.com; www.bruker.com; www.shimadzu.com; 
www.advandx.com; www.miacom-diagnostics.com; www.gen-probe.com; 
www.nanosphere.us; www.roche.com; www.seegene.com; www.cepheid.com; 
www.sirs-lab.de; www.molzym.com; www.ibisbiosciences.com). 
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1.2.1 Blood culture as a gold standard method 
Blood culturing is the current gold standard method for determination of causative agents 
in case of sepsis and BSI. Blood sample is taken from the patient and inoculated in 
aerobic and anaerobic blood culture bottles containing suitable growth media for micro-
organisms. According to Clinical and Laboratory Standards Institute (CLSI) guidelines 
for blood culture (2007), two to three different sets of blood cultures per septic episode 
are recommended. During the 24 hour period, no more than three sets are typically 
needed (Ntusi et al., 2010). The blood volume inoculated to the blood culture bottle varies 
between manufacturers. According to CLSI (2007), suitable sample volume would be 20-
30 mL from adults per culture and no more than 1 % of infant’s total blood volume. 
Typical dilution ratio of blood in broth is ≥ 1:5 and maximum blood volume varies 
between bottle types, starting from 10 mL (CLSI, 2007; Reimer et al., 2005; Ntusi et al., 
2010). Nowadays most of the laboratories use automated blood culture systems in which 
fluorometric or colorimetric sensors continuously monitor bottles. The detection of 
positive reaction is based on either increasing CO2 production or headspace gas pressure. 
Examples of well-established automated blood culture systems are BACTEC™ FX/9000 
series (Becton Dickinson, USA), BacT/ALERT series (bioMérieux, France) and 
VersaTREK (Thermo Fisher Scientific, USA) (CLSI, 2007; Weile and Knabbe, 2009). 
Blood culture bottle incubation time varies, but a large portion of pathogens can be 
detected after 24 hours incubation. Nearly 100 % of pathogens can be detected after 4-5 
days incubation and some recommendations range up to 7 days before blood culture is 
classified as negative if no growth has been detected (Coccerill III et al., 2004; Ntusi et 
al., 2010).  
 
After a blood culture has been flagged positive, further investigation of the causative 
agent is performed with subculturing on appropriate media and investigating 
morphological features and cell wall characterization by staining and microscopy (e.g. 
Gram stain, Ziehl-Neelsen stain) (CLSI, 2007; CLSI, 2011). In addition, antimicrobial 
susceptibility evaluation is performed together with subculturing. CLSI (2011) guidelines 
list the most typical microbes and antimicrobial resistances which should be tested in a 
routine laboratory. For example MRSA findings are increasing and when Staphylococcus 
spp. has been detected from the sample, oxacillin susceptibility testing is recommended 
(CLSI, 2011).  
 
1.2.2 Phenotypic-based characterization of microbes 
Rough characterization of pathogens by staining and microscopy may already guide 
clinicians to revise antimicrobial treatment. Typically, species identification is still 
achieved by culturing on appropriate media followed by pattern of biochemical tests such 
as catalase production and oxidase reaction. These tests give an overview of bacterial 
biochemical properties and can be used for identifying bacteria. Biochemical test may be 
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performed as single manual tests but several automated systems are commercially 
available allowing high-throughput analysis. Examples of well-established automated 
systems are VITEK
®
 (BioMérieux, France), BD Phoenix™ (Becton Dickinson, USA) and 
Microscan WalkAway
®
 (Siemens Healthcare Diagnostics, Germany). Most of the systems 
perform pathogen identifications by screening biochemical properties and antimicrobial 
susceptibility testing by serial dilution (Houpikian and Raoult, 2002; Klouche and 
Schröder, 2008; CLSI, 2007). 
 
Phenotypic methods have been used as a standard microbiological procedure for pathogen 
identification from positive blood culture. Although it is used as a reference method when 
new technologies are developed, some limitations can be still identified. Phenotype-based 
characterization requires pure bacterial culture which prolongs the time to identification 
especially in case of slow growing and fastidious bacteria. Old cultures may not show 
typical biochemical patterns as expected, and variation may be found between different 
strains from the same species, which may affect the accuracy of species-level 
identification. Ongoing antimicrobial therapy may affect the typical biochemical 
properties of pathogens. Databases used for interpretation and comparison of pathogens’ 
biochemical properties may also contain limited number of species (Kim et al., 2008, 
Weile and Knabbe, 2009).      
 
In addition to investigating bacterial biochemical properties, immunoassays allow the 
detection of antigens or presence of specific antibodies raised in response to pathogen 
antigens. Several immunoassay formats such as enzyme immunoassays, 
immunofluorescent assays and latex agglutination assays are available (Weile and 
Knabbe, 2009; Houpikian and Raoult, 2002). MRSA-Screen latex agglutination test 
(Denka Seiken Co., Ltd., Japan) is one of the immunoassays used for screening MRSA. 
The assay uses a monoclonal antibody for the detection of PBP2a and the results are 
obtained in around 20 minutes. The sensitivity has been shown to be at a sufficient level 
for accurate detection (Atay and Gülay, 2004). 
       
1.2.3 Protein-based characterization of microbes 
Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-
TOF MS) has been originally used as a research tool for protein analysis and it’s use has 
recently emerged also in clinical microbiology and sepsis diagnostics. Pathogens from 
positive blood culture are subcultured and growth colonies can be used for analysis by 
MALDI-TOF MS. During sample analysis, the device forms a mass-to-charge ratio 
spectrum with peaks indicating the molecular masses and charge densities of components 
present in a biological sample. The measured peaks, generated from ionization of highly 
conserved proteins are compared against the reference spectra of the integrated database 
provided by the manufacturer. Species and genus identification is based on the 
comparison of peaks to reference spectra. Scores calculated by comparing the spectra 
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indicate the confidence of identification (Cherkaoui et al., 2010; Kaleta et al., 2011).  
Analysis does not require operation with batches and the method is considered to be fast. 
Reagent costs are low but a device investment is expensive. Subculturing is still required 
which lengthen the analysis time but development is also ongoing to use blood culture as 
a sample type. Some limitations have been found with the sensitivity and specificity in 
case of multi-infection samples, as well as with the coverage of target panel. Also, 
evaluations of antimicrobial susceptibilities are still limited. Well known MALDI-TOF 
MS manufacturers are e.g. Bruker (Germany), BioMérieux (France) and Shimadzu 
Corporation (Japan) (Cherkaoui et al., 2010; Kaleta et al., 2011; La Scola and Raoult, 
2009). 
 
1.2.4 Pathogen identification by nucleic acid- and hybridization-based 
assays 
NA- and hybridization-based assays require a large number nucleic acids of target cells 
and therefore are often targeted to ribosomal ribonucleic acids (rRNA) molecules which 
are present in high copy numbers per cell (Weile and Knabbe, 2009; Klouche and 
Schröder, 2008). Fluorescence- and chemi-luminescence-based assays are available for 
pathogen identification from positive blood culture samples. These include PNA-FISH 
(AdvanDX, USA), HemoFISH assays (miacom, Germany) and AccuProbe (Gen-Probe 
Inc, USA) (Asfari et al., 2012; Peters et al., 2004; Miacom Diagnostic, 2011). The most 
commonly used hybridization-based assay utilizes a fluorescent in situ hybridization 
(FISH) technology, which is based on fluorescently labeled species specific probes 
hybridizing to conserved regions of rRNA in bacterial cells. Different probes are labeled 
with different fluorochromes and when the hybridized sample is viewed under a 
fluorescence microscope, pathogens can be distinguished based on the fluorescence 
signals (Bauerfiend et al., 2012; Miacom Diagnostic, 2011, Harris and Hata, 2013). While 
studies using PNA-FISH have shown that identification is achieved faster than with 
conventional methods, some limitations are still identified. Depending on the diagnostic 
need, a suitable kit detecting a certain number of pathogens can be chosen based on 
Gram-staining results. Thus, results might be needed simultaneously from several 
different FISH-based assays since one assay may identify only few targets. There also 
might be sensitivity problems in case of slow growing and fastidious organism since 
PNA-FISH requires at least 10
5
 colony forming units (CFU) per mL for positive detection 
(Harris and Hata, 2013). 
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1.2.5 Pathogen identification by nucleic acid- and amplification-based 
assays 
Polymerase chain reaction (PCR) is maybe the most common amplification method used 
in molecular assays. The starting material for PCR is deoxyribonucleic acids (DNA) and 
therefore many complex sample types, such as blood culture and tissue require sample 
preparation and NAs extraction steps before amplification. Two types of primers are 
generally used: species specific primers targeted to certain bacterial or fungal gene areas 
or to genes responsible for resistances, and universal broad-range primers which are 
typically targeted to conserved gene regions, amplifying a high number of different 
pathogens using the same set of primers. Both primer strategies can be combined in 
multiplex PCR, where several gene targets are amplified in the same reaction (Peters et 
al., 2004; Dark et al., 2009). Typical genes and regions which are generally used for 
taxonomical characterization, and also in many commercial assays, are 16S rRNA, 
gyrB/parE genes and internal transcribed spacer (ITS) region. These contain highly 
conserved areas flanking variable areas for accurate distinguishing of bacterial or fungal 
species (Wellinghaussen et al., 2009; Casalta et al., 2008; Metso et al., 2013). Ribosomal 
16S rRNA gene and ITS region are present in high copy numbers in cells. gyrB/parE are 
single-copy genes encoding small subunits of type II and IV topoisomerases, respectively, 
which regulate the over- or underwinding of DNA during the replication period (Forterre 
et al., 2006; Soraya et al., 2008). 
 
Two types of PCR assays are available; real-time PCR and conventional end-point PCR 
assays. Real-time PCR enables detection and simultaneous quantification of targeted 
DNA molecules during amplification, representing the key advantage of these assays. 
Amplified products are labeled either with non-specific fluorescent dyes (e.g. SYBR 
green) which binds to the any double stranded DNA (dsDNA) or labeled probes which 
hybridize to a specific sequence of the target organisms (e.g. molecular beacons, Taqman 
probes). Several probes with different fluorochromes may be used for differentiation of 
target organisms in the same reaction. Result interpretation is based on fluorescent signal 
monitored during the amplification. Well-studied multiplex real-time PCR assays directed 
to the identification of sepsis causing bacteria from whole blood samples are 
LightCycler
®
 SeptiFast Test MGRADE (F. Hoffmann-La Roche, Germany) and 
MagicPlex (SeeGene, South-Korea). In addition, one example of multiplex real-time PCR 
assays using positive blood culture sample type is Gene Xpert MRSA/MSSA assay 
(Cepheid, USA) (Dark et al., 2009; Josefson et al., 2011; Heid et al., 1996).  
 
Conventional end-point PCR is a standard PCR reaction, containing either species-
specific or broad-range primers for amplification. The end product of the PCR reaction 
are dsDNA or single stranded DNA (ssDNA) amplicons, which can be further analyzed 
by a detection method such as gel electrophoresis, sequencing, hybridization on a 
microarray or electrospray ionization mass spectrometry (ESI-MS). Increasing numbers 
of alternative detection technologies are being developed with various advantages and 
result interpretation is dependent on the used method (Afshari et al., 2012; Klouche and 
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Schröder, 2008; Mancini et al., 2010). Some protocols may be time-consuming and 
require educated/skilled personnel (Dark et al., 2009). Examples of end-point PCR assays 
using different detection technologies are VYOO
®
 (Sirs-Lab, Germany), SepsiTest
®
 
(Molzym GmbH & Co., Germany) and PLEX-ID (Abbott Ibis Bioscience, USA). 
 
VYOO
®
 is a PCR and gel electrophoresis assay directed to whole blood samples. Gel 
electrophoresis enables size-based separation of different fragments and indicates the 
success of amplification step (Fitting et al., 2012). Amplicons can be further analyzed by 
sequencing and sequence homology searches for identification of the pathogen. 
SepsiTest
®
 utilizes gel electrophoresis and sequencing technology from whole blood 
samples (Wellinghausen et al., 2009). Amplicon analysis by PCR-ESI-MS is a new 
detection method in sepsis diagnostic. PLEX-ID is a PCR-ESI-MS device following the 
same principle than MALDI-TOF but instead of analyzing proteins, the device uses 
amplicons for characterization. The mass to charge ratios of PCR amplicons are measured 
and the obtained spectrum is compared to a reference database for pathogen 
identification. The system uses both culture and whole blood sample types and it has been 
also used for epidemiological purposes (Kaleta et al., 2011; Afshari et al., 2012; Soraya et 
al., 2008). 
1.2.5.1 DNA Microarray-based assays 
Hybridization on a DNA microarray is one of the detection strategies for analysis after 
end-point PCR. This approach was also used in this study when molecular assays for 
sepsis diagnostics were developed. The key advantage of microarrays is the potential of 
simultaneous identification of a large panel of pathogens and detection of resistance 
markers (Soraya et al., 2008). DNA microarrays contain DNA fragments or 
oligonucleotide probes which are immobilized onto a chemically modified solid surface 
such as a glass or silica slide. Depending on the amount of targets and oligonucleotide 
probes, arrays can be distinguished into high-density (around 10
4
-10
6
 probes) or low-
density (around 100-1000 probes) arrays. Oligonucleotides are typically short 20-30 base 
pair (bp) long synthetic ssDNA products which are covalently attached to the surface for 
example via amino modifications in the 5’-terminus. One oligonucleotide probe may be 
printed on the microarray as duplicate or triplicate. This printing strategy can improve 
detection of target DNAs instead of unwanted interfering substances. The amount of 
replicates is however fully dependent on the detection strategy. Oligonucleotide probes 
are designed for variable regions of the gene target and several different specific probes 
may be designed per each target in order to confirm the detection of target organism 
(Cleven et al., 2006; Ulyashova et al., 2010; Cuzon et al., 2012; Roth et al., 2004; Weile 
and Knabbe, 2009).  
 
After an amplification of target DNA from a sample, labeled ssDNA amplicons are 
hybridized with oligonucleotide probes using suitable conditions and reagents. Probes are 
printed on the microarray in a certain order and the pathogen can be identified when 
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hybridization is detected with the specific probes. Several studies have been published 
using microarray with colorimetric or fluorescent detection technology (Roth et al., 2004; 
Cuzon et al., 2012; Wiesinger-Mayer et al., 2011). Shortly, one colorimetric detection 
method, which was employed also in this study, is based on biotin labeled DNA 
fragments which are hybridized with complementary probes on the microarray. During 
the conjugation step, streptavidin-horseradish peroxidase (HRP) conjugate binds to biotin. 
In the final precipitation step, HRP catalyzes the oxidation of the chromogenic substrate 
3,3’,5,5’-tetramethylbenzidine (TMB) or its analogue inducing a blue reaction-product. 
The reaction is visualized by camera with a visible light source. Fluorescent detection is 
based on fluorochrome-labeled amplicons which are hybridized with probes on the 
microarray and detected with a fluorescence reader. Both detection technologies contain 
several carefully optimized steps which provide suitable conditions for hybridization, for 
example to decrease the interfering background signal level and promote good spot 
morphology for detection (Sauer et al., 2009; Cuzon et al., 2012).  
 
Signal intensities from each hybridization complexes are calculated and compared to the 
background signal. Sophisticated analysis software is typically used for analysis of 
microarray images and interpretation of detected spots facilitated by built-in analysis 
rules. In optimal cases, identified pathogens or gene markers are reported without result 
interpretation by user. However, building complex functional analysis algorithms is time-
consuming and many published studies report manual microarray result analysis 
(Wiesinger-Mayer et al., 2011). An example of an assay utilizing hybridization 
technology for identification of pathogens from positive blood culture is the Verigene
®
 
assay (Nanosphere Inc, USA) (Anderson et al., 2012).  
 
1.2.5.2 Challenges in sample preparation in sepsis diagnostics 
Sample preparation and NA extraction are critical steps in molecular assays, because 
efficient extraction is required for further NA analysis. Point-of-care (POC) assays 
contain sample processing and analysis in one closed system. However, a majority of 
molecular assays include only downstream analysis steps and a method for sample 
processing is needed separately (Anderson et al., 2012; Weile and Knabbe, 2009).  
 
Blood culture and whole blood are the main sample types for assays used for sepsis 
diagnostics. These sample types cause challenges to sample preparation and selection of 
an appropriate NA extraction method. The ability to disrupt microbial cell walls is 
important since Gram-positive bacteria as well as fungi contain cell walls which are 
harder to lyse. Sample material may contain low amounts of causative pathogens such as 
1-30 CFU/mL in whole blood, and therefore recovery of microbial DNA in extraction 
should be high. Removal of inhibitors such as heme, anticoagulants (e.g. 
Ethylenediaminetetraacetic acid (EDTA)) and heparin from blood samples is important 
for amplification (Ecker et al., 2010; Al-Sould et al., 2000). Blood samples contain also 
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high amounts of human DNA which may interfere with the amplification of microbial 
DNA. Extraction methods designed to remove human DNA may increase the sensitivity 
of amplification. Suitable sample and eluate volumes should be optimized for the 
downstream application. Several user requirements need to be taken into account in assay 
design and development such as high reproducibility, required level of automation, 
throughput requirements, cost-effectiveness, user-friendliness and flexibility of methods 
(Horz et al., 2009; Regueiro et al., 2010). 
 
Many automated high-throughput and semi-automated extraction devices are available 
such as NucliSENS
®
easyMAG
®
 (bioMérieux, France), MagNA Pure LC (F. Hoffmann-
La Roche, Germany), EZ1
®
 (Qiagen, Germany) and NorDiag Arrow (NorDiag, Norway). 
These devices employ different extraction kits for different purposes. Also manual kits for 
lower sample throughput are available. Extraction methods typically utilize chaotropic 
agents for lysis and silica particles, magnetic beads or silica columns for binding of 
released NAs (Wiesinger-Mayer et al., 2011, Bergman et al., 2013; Brownlow et al., 
2012). Typically these extraction solutions, evaluated for blood or blood culture sample 
material, extract total NAs including human and microbial NAs from the clinical sample. 
Only few methods have concentrated on the separation and extraction of microbial DNA 
from total NAs. Molzym GmbH & Co. (Germany) is one company offering manual and 
semi-automated solutions for microbial DNA extraction from whole blood samples. The 
method first enzymatically degrades human DNA and then extracts microbial DNA from 
concentrated microbial cells (Wiesinger-Mayer et al., 2011).   
 
1.2.6 Comparison of gold standard method with novel technologies 
A high amount of rapid assays have been developed for the detection of causative 
pathogens from patients with suspected sepsis or BSI. None of those assays have replaced 
the current gold standard blood culture method but are valuable tools, especially when 
directed to certain groups of patients under higher risk (Paolucci et al., 2010; Soraya et 
al., 2008). In situations where the conventional method fails to identify the causative 
agent, molecular assays may enable faster and more targeted management of patients.  
Genotype-based characterization has already opened a new era and brought broadened 
perspective to the conventional culturing method in microbiological laboratories (Mancini 
et al., 2010; Soraya et al., 2008; Klouche and Schröder, 2008). 
 
The main disadvantages of current blood culturing and further subculturing method are 
the delay of results and low sensitivity in case of slow growing bacteria and fungi. 
Occasionally, if the patient does not respond to initial therapy, the clinician may need to 
change the empirical therapy before the blood culture has turned positive (Paolucci et al., 
2010). Around 30-40 % of all blood cultures taken for the diagnosis of BSIs turn positive 
and large amounts remain negative even if there is a strong clinical suspicion of infection 
(Klouche and Schröder, 2008). False negative blood cultures may be due to the previous 
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use of antimicrobial treatment, insufficient volume of blood cultured, fastidious and slow 
growing pathogens or for example bacterial production of toxins, such as toxic shock 
syndrome toxin 1 by S. aureus or pyrogenic toxins by S. pyogenes (Liang et al., 2013; 
Ross and Onderdonk, 2000; Carrigan et al., 2004; Nguyen et al., 2006; Klouche and 
Schröder, 2008). Some bacteria are sensitive to growth conditions and inappropriate pre-
analytic handling may disturb exponential growth. Studies have also reported problems 
with skin flora contamination in the blood culture bottles. The fraction of false positives 
depends on the used system or media and may range from 0.6 % to over 6 % (Klouche 
and Schröder, 2008; Hall and Lyman, 2006). However, blood culture is still a valuable 
method in the detection of microbes and after bacteria have been detected from blood 
culture bottles, susceptibility testing can be started and suitable therapy administered 
(Klouche and Schröder, 2008; Dark et al., 2009). Lots of effort has been put to improve 
blood culture method by developing higher level of automation and new growth media 
with inhibitor-neutralizing agents. Correct timing in taking blood samples, suitable blood 
volume and sufficient amount of blood samples taken per set may increase sensitivity and 
detection of real causative agents instead of contaminants (Paolucci et al., 2010; Hall and 
Lyman, 2006; Coccerill III et al., 2004).  
 
The advantage of molecular assays is the time benefit in the identification of pathogens, 
which is critical for appropriate antimicrobial therapy. Dependent on the panel of used 
molecular assays, typically most of the important pathogens and resistance markers can 
be screened within one analysis. Molecular assays can also detect slow growing and 
fastidious organism which typically require several days of culturing by the conventional 
method. NA assay does not necessarily require viable microbes, enabling detection of 
pathogen DNA after antimicrobial treatment and identification of autolysed pathogens 
(e.g. S. pneumoniae) (Paolucci et al., 2010; Martner et al., 2009). However, analysis with 
molecular assays is not always unambiguous. Interpretation of findings may be difficult 
and the significance of pathogen DNA as a marker of infection is under investigation. 
Complicating the interpretation, there is a lack of reference method especially when 
assays are performed directly from whole blood (Dark et al., 2009; Paolucci et al., 2010). 
Furthermore, an adequate sensitivity is difficult to achieve due to the low pathogen 
concentrations in whole blood. Some assays have difficulties also in differentiating 
pathogens in the case of multi-infections (La scola and Raoult, 2009).  
 
Molecular assays face additional problems such as environmental contaminants (e.g. skin 
contaminants), bioburden coming from reagents (e.g. genomic DNA from host bacteria 
during the production of polymerases) or manufacturing processes (Ecker et al., 2010; 
Mühl et al., 2010). Strict rules and guidance for collection and preparation of samples 
could lower the level of contaminants. Lots of work has also been done to improve 
industrial processes to develop DNA-free reagents. In addition, clinical relevance of 
DNAemia/circulating DNA or negative results by molecular assays and their influence on 
patient condition are under intensive investigation (Dark et al., 2009; Klouche and 
Schröder, 2008; Peters et al., 2004).  
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Cost issues are always a question since traditional culturing method is relatively cheap 
and molecular assays typically bring higher costs. Some new assays for sepsis diagnostics 
require also expensive initial device investment. However, every additional day in 
hospital ward causes substantial costs and thus novel methods, bringing earlier results, 
can decrease the length of stay and related cost in hospital (Agnus et al., 2001). Lodise 
and co-workers (2003) demonstrated that a delay in appropriate antimicrobials for S. 
aureus bacteremia by over 45 hours increased length of hospital stay from 14 to 20 days. 
Also Davis and co-workers (2012) presented in their cost-benefit analysis that longer 
patient treatment in hospital causes higher expenses.  
 
1.3. Validation of new assays for diagnostics: regulation and 
legislation  
New assays for diagnostics are designed and developed according to the in vitro 
diagnostic (IVD) regulations. IVD products offered for sale in EU member countries are 
required to conform to IVD directive requirements and to be IVD-Conformité 
Européenne (CE) marked. Generally, IVD tests are medical devices, including reagents, 
instruments etc. which are intended to be used for the examination of human specimens 
(e.g. blood, tissue) and producing medically important information. CE mark represents 
conformity of the IVD product to the in vitro diagnostic medical device directive (IVDD) 
98/79/EC. Requirements for attaining CE marking include particular verification and 
validation of technical characteristics. Demonstration of performance must include for 
example sensitivity and specificity determinations, accuracy, repeatability, 
reproducibility, including control of known relevant interference, and limit-of-detection 
determinations. The 98/79/EC directive specifically defines important terms and its 
purpose is to ensure that only safe and functional products are placed on the market in EU 
countries. EC declaration of conformity is the procedure whereby the manufacturer who 
fulfills the requirements of IVDD declares that the product meets all the provisions which 
apply (Directive 98/79/EC, 1998).  
 
Manufacturers often follow harmonized international standards which help to meet the 
specified requirements for IVDs, such as International Organization for Standardization 
(ISO) 9001 and ISO 13485 standards. ISO 9001 is a quality management system standard 
applicable to many industries. ISO 13485 is a standard specific to medical device quality 
management systems. Being ISO 13485 certified is the industry standard of ensuring and 
communicating that the quality management system of the company complies with 
98/79/EC directive (SFS-EN-ISO-9001, 2008; SFS-EN-ISO-13485, 2004). 
 
In the US, similar regulations and guidance are implemented by the US Food and Drug 
Administration (FDA). In contrast to the separate regulations of medical devices and IVD 
directives in Europe, the same medical device regulations apply to IVD's as any other 
medical device in the US. FDA classifies IVD's based on medical risk to Class I-III, 
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where Class I contains low risk devices and Class III contains high risk devices. Standard 
ISO 13485 is also recognized by FDA and Quality System Regulations (21CFR Part 820) 
are consistent with ISO 13485. In general, FDA guidance is more prescriptive than the 
EU IVDD and can be used in the development of an IVD for Europe (FDA, 2013; 
Kimmelman, 2003). When new IVD assays are developed, both EU IVDD and FDA 
regulations should be considered carefully with regard to intended market scope.  
 
1.3.1 Estimation of sensitivity and specificity 
CLSI is an international organization which develops worldwide recognized consensus 
standards and guidelines for patient testing and related health care issues. It has produced 
guidelines for qualitative diagnostic tests in order to standardize the experimental details 
as well as the data analysis of qualitative information. When new diagnostic assays are 
developed, validation can proceed according to these CLSI guidelines. These guidelines 
were also followed in the clinical validation of the molecular assay developed in this 
study. 
 
According to the guidelines (CLSI, 2002; CLSI, 2006; CLSI, 2008), comparison of 
results should be made against a reference (gold standard) method and optionally also 
other methods which are in routine use in the laboratory. When results are compared with 
patient samples whose clinical diagnosis is known, the results should be treated separately 
from the comparison results with the reference method. Comparison of the results from 
test method and reference procedure allows categorizing the data into true positive (TP), 
true negative (TN), false positive (FP) and false negative (FN) results. The result of the 
tested method is TP if test result gives the same positive identification as the reference 
test result. Similarly, the result is TN if both the test result and the reference result are 
negative. The result of the tested method is FP if the test result is positive and the 
reference result is negative. Similarly, the test method result is FN if the test result is 
negative while the reference result is positive. If the clinical diagnosis for the patient 
specimen is known, the obtained test results may be separately compared with the clinical 
diagnosis and separate values calculated thereby. These values are used for the estimation 
of parameters such as specificity and sensitivity for the assay. Formulas for calculating 
sensitivity and specificity are presented below (CLSI, 2002; CLSI, 2006; CLSI, 2008). 
 
Estimated sensitivity = TP / (TP + FN) 100 %  
 
Estimated specificity = TN / (TN + FP) 100 %      
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During the evaluation of the test method, samples are typically a selection of the 
specimens and it may cause variability to the measures. This variability can be estimate 
quantifying confidence limits. CLSI guidelines (2002; 2006; 2008) recommend using 
score confidence limits for calculation and the formula for 95% score confidence interval 
(CI) for sensitivity and specificity is described below. Number 1.96 is the quantile from 
standard normal distribution that corresponds to 95% confidence. 
 
95% score confidence interval = 100 % (Q1 – Q2)/ Q3 and  100 % (Q1 + Q2)/ Q3   
 
For sensitivity calculations    For specificity calculations   
Q1 = 2TP + 1.96
2
      Q1 = 2TN + 1.96
2
  
Q2 = 1.96 1.96
2 +
4 TP * FN
TP + FN
    Q2 = 1.96 1.96
2 +
4 FP * TN
FP+ TN
 
Q3 = 2 (TP + FN + 1.96
2
)     Q3 = 2 (FP + TN + 1.96
2
) 
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2 Aims of the study  
Bacterial sepsis is a life-threatening disease with high rates of morbidity and mortality. At 
the moment, blood culturing is the gold standard method for determining the causative 
bacteria for sepsis. The procedure is highly manual and bacterial identification together 
with antimicrobial sensitivity profiling requires typically 2-5 days. To improve 
diagnostics and start species specific therapy earlier, new approaches are needed for rapid 
identification of sepsis causing bacteria. The main goal of this study was to develop and 
optimize a PCR- and microarray-based assay for in vitro diagnostic use for identification 
of sepsis and/or BSI causing bacteria. The study focused also to review DNA extraction 
methods suitable for the developed diagnostic assay. Another aim was to evaluate the 
PCR and microarray assay’s suitability for identification of pathogens directly from 
whole blood samples without a culturing step. 
 
 
The specific aims of this study were to: 
 
 Develop a PCR- and microarray-based assay for the detection of sepsis 
causing bacteria using clinical isolates. Evaluate the performance of the assay 
with blood culture samples and demonstrate proof-of-concept (Publication I). 
 
 Improve the bacterial panel of the assay to cover the important sepsis causing 
bacteria and clinically validate the assay’s suitability to sepsis diagnostics 
using blood culture samples (Publication II). 
 
 Improve the assay’s ability to rapidly analyze large sample set by optimizing 
the assay to a higher-throughput platform allowing a run of 1- 96 samples at a 
time (Publication III). 
 
 Investigate the efficiency of sample preparation methods for extraction of 
bacterial DNA from blood culture samples (Publication III).    
 
    
 Evaluate the suitability of the developed PCR and microarray assay to detect 
sepsis causing bacteria directly from whole blood (Publication IV). 
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3 Materials and methods 
Blood culture samples and clinical isolates used in this study are described in detail in the 
original publications. The division of these samples is presented in Table 3. A total of 
3595 blood culture samples were freshly collected and analyzed. 2716 samples were 
collected from Helsinki University Hospital Laboratory (HUSLAB), Helsinki, Finland 
(Publications I, II and III), and 879 samples from University College London Hospital 
(UCLH), London, UK (Publication II). Blood samples were obtained from patients with 
suspected sepsis and were further cultured in aerobic or anaerobic blood culture bottles 
according to the standard laboratory protocols in those laboratories. 2344 of these samples 
were blood culture positive and 1251 were blood culture negative.  
 
Clinical isolates were collected from American Type Culture Collection (ATCC, US), 
Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Germany), 
HUSLAB (Finland) or from the culture collection of Mobidiag Oy, (Finland). A total of 
156 clinical isolates were analyzed during the study. Tables 2 and 3 from original 
publication I and Tables 2 and 3 from original publication IV present the clinical isolates 
used in those papers. All the methods used in this study are described in detail in the 
indicated articles and are summarized in Table 4. 
Table 3. Blood culture samples and clinical isolates used in this study. 
Publications Sample type  Number of samples 
I 
Blood cultures  186 
       Positive blood cultures 146 
       Negative blood cultures 40 
Clinical isolates 129 
II 
Blood cultures  3318 
       Positive blood cultures 2107 
       Negative blood cultures 1211 
Clinical isolates - 
III 
Blood cultures  91 
       Positive blood cultures 91 
       Negative blood cultures 0 
Clinical isolates 1 
IV 
Blood cultures  - 
       Positive blood cultures - 
       Negative blood cultures - 
Clinical isolates 26 
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Table 4. Methods used in the study. The Roman numerals refer to the original articles in 
which the methods were applied. 
Methods Publications 
Bacterial culturing   
Culturing on agar plates I, III, IV 
Blood culturing I, II, III 
DNA extraction   
Manual boiling method I, IV 
Extraction by NucliSENS
®
 easyMAG
®
 device I, II, III, IV 
Extraction by NorDiag Arrow device   
     - Viral NA kit III 
     - Blood pathogen DNA isolation kit IV 
Spectrophotometer measurements   
Optical density (OD) III, IV 
DNA concentration and purity III, IV  
Amplification    
Primer design I 
PCR amplification I, II, III, IV 
Real-time PCR for E. coli III 
Microarray experiments   
Capture oligonucleotide design I, II 
Manufacturing of microarray and spotting of capture probes  § I, II 
Hybridization onto TubeArray I, II 
Hybridization onto StripArray III, IV 
Design of target identification rules I, II 
Other DNA analysis methods   
Sequencing I, II, III  
Image analysis by agarose gels I 
Analysis by reference gold standard method   
Blood culturing and phenotypic based characterization I, II, III 
Antimicrobial susceptibility evaluation I, II, III 
Assay sensitivity / specificity calculations I, II, IV 
 
 
§ Construction of TubeArray and StripArray microarrays and spotting of oligonucleotides 
were performed by Clondiag GmbH (Germany) using their standard protocol for 
microarray manufacturing. Oligonucleotides were 5'-amino-modified prior to spotting on 
the microarray.   
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4 Results and discussion 
4.1 Development of multiplex-PCR and microarray assay for 
sepsis diagnostics 
4.1.1 Set up of PCR and microarray assay (I) 
In this study, the assay which consists of an end-point PCR followed by hybridization and 
colorimetric detection on a low-density microarray for identification of bacteria was 
designed. Broad-range bacterial primers targeted to conserved regions of the gyrB and 
parE genes were modified using inosines from the primers introduced originally by Roth 
and co-workers (2004). In addition, species specific primers targeted to S. aureus 
gyrB/parE genes and specific primers targeted to the mecA gene were designed and added 
to the PCR reaction. The optimized multiplex-PCR protocol for these primers produced 
ssDNA during the amplification step. dsDNA was exponentially produced in the first 
PCR phase followed by ssDNA production in the second PCR phase. A slightly similar 
type of PCR method was introduced by Zhu and co-workers (2007). The performance of 
primers described by Roth and co-workers (2004) and re-designed gyrB/parE primers was 
compared by gel electrophoresis method and sensitivity was shown to be at least on the 
same level for the bacteria included in the assay panel. Also the production of ssDNA by 
the re-designed gyrB/parE primers was demonstrated (Publication I: Fig. 1). 
  
Oligonucleotide probes were printed as duplicates onto a microarray placed at the bottom 
of a 2 mL tube (Prove-it™ TubeArray, Figure 1). Since ssDNA was produced during the 
PCR reaction, hybridization could be performed straight after the PCR step and common 
methods of ssDNA production such as alkaline, heat treatment or asymmetric PCR were 
avoided (Gao et al., 2003; Gyllensten and Erlich, 1988). The colorimetric hybridization 
protocol was optimized carefully for efficient hybridization on the microarray. Positive 
hybridization spots were detected by a reader instrument including camera and light 
source (Prove-it™ TubeArray reader, Figure 1). Target identification rules based on spot 
detection were tested and implemented to the analysis software Prove-it™ Advisor 
(Figure 3). These identification rules and spot detection threshold values were also 
evaluated and improved during the optimization of the assay. 
 
Approximately 20 bp long probes were targeted to the gyrB/parE or mecA genes. The 
cross-hybridization with sequences of non-targeted bacteria were attempted to avoid 
using various in silico- parameters during the design of the probes after which the 
accuracy of the probes were evaluated empirically. Species specific oligonucleotides were 
successfully designed for the detection of A. baumannii, E. faecium, Enterococcus 
faecalis, H. influenzae, K. pneumoniae, Listeria monocytogenes, N. meningitidis, S. 
aureus, S. epidermidis, Streptococcus agalactiae, S. pneumoniae and Streptococcus 
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pyogenes. Genus-specific probes were designed for selected CNS species and in addition, 
mecA specific probes were included for detection of methicillin-resistance (Publication I: 
Table 1). The chosen target panel contained pathogens causing severe infections such as 
sepsis and also common resistant bacteria (Vincent et al., 2006; Trouillet et al., 1998). 
  
In order to evaluate the specificity of the designed oligonucleotide probes and 
hybridization protocol, 102 clinical isolates of 70 untargeted bacteria comprising 
clinically relevant bacterial species, closely related species of targeted bacteria and also 
bacteria of human normal flora were tested (Publication I: Table 3). Amplicons were 
hybridized to the microarray and the reported identifications by Prove-it™ Advisor were 
compared to the known identification data of the samples. The cross-reaction study 
reported only one discrepant result when K. pneumoniae subsp. ozenae was reported as K. 
pneumoniae subsp. pneumoniae. In conclusion, the results showed high specificity for the 
PCR and microarray assay. 
 
 
Figure 1 The microarray platform including a low-density microarray with oligonucleotide 
probes at the bottom of a 2 mL tube (Prove-it™ TubeArray) and specific 
colorimetric reader for detection of hybridization reactions from the microarray. 
Identification of target(s) is based on built-in analysis rules and is reported by the 
Prove-it™ Advisor software. 
4.1.2 Performance evaluation and proof-of-concept of the assay (I) 
In order to evaluate the proof-of-concept and performance of the designed end-point PCR 
and microarray assay for the detection of sepsis causing bacteria, a set of 186 blood 
culture samples, including 146 positive and 40 negative blood cultures from HUSLAB 
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(Finland) were blindly tested. DNA from the samples was first extracted by the 
NucliSENS
®
easyMAG
®
 device followed by the PCR and microarray analysis.  
 
Bacteria were identified originally from 69 positive blood cultures by the PCR and 
microarray assay. The most frequently isolated bacteria were S. aureus, E. faecalis, S. 
epidermidis and K. pneumoniae. These microbes are common causative agents in sepsis 
(Beekman et al., 2003; Schmitz and Lehmann, 2011). The assay reported negative results 
from 117 blood cultures, of which 40 were blood culture negative samples (Publication I: 
Table 4). The negative result was correctly reported from species such Bacillus sp., E. 
coli, and E. cloacae which were not included in the target panel of the PCR and 
microarray assay. 
 
Results were compared to culturing and 17 discrepant results were observed (Publication 
I: Table 4). In the two false positive samples, the microarray assay detected the mecA 
gene marker with the atypical species S. pneumoniae and E. faecalis for an undetermined 
reason. However, comparison of the results with the reference method showed that the 
bacterial identifications (S. pneumoniae and E. faecalis) were similar with the blood 
culture results. Six samples reported as false negative contained CNS species not included 
in the CNS panel of the microarray assay and thus were determined to be true negatives. 
In three samples, the assay did not detect S. pyogenes, S. aureus or S. epidermidis for 
undetermined reason. Those samples were thus calculated as false negatives. DNAs from 
these three samples were also amplified by 16s rDNA PCR, but no amplifications were 
detected indicating possible PCR inhibitors or degraded DNA in the samples.  
 
In addition, six samples containing either S. agalactiae, S. epidermidis, S. pneumoniae, E. 
faecalis, E. faecium, or S. aureus  were originally reported as false negative caused by 
either one fully negative probe hybridization signal or one weaker probe hybridization 
signal. Other duplicates and probes were correctly detected by the Prove-it™ Advisor 
analysis software, but the results remain under the positive identification criteria and thus, 
samples were reported as negative. When evaluating less precise identification rules, all 
of these samples were identified successfully by the microarray assay. These results were 
also in line with blood culturing results and thus were determined to be true positives 
when calculating the final specificity and sensitivity values. Evaluating the suitable spot 
detection threshold and building optimal detection rules for accurate identification of all 
pathogens by microarray is very challenging and requires several revise cycles (Imbeaud 
and Auffray, 2005). Such adjustments after the analysis would not be appropriate in a 
diagnostic assay and thus accurate pathogen identification should be improved by 
designing new oligonucleotide probes, experimentally setting the best-functioning 
detection threshold values and formulating efficient identification rules.  
 
Based on the results the initial assay sensitivity was calculated to be 82 %. However, 
when the described adjustments in the identification of the six samples were done, the 
final sensitivity of the assay was determined to be 96 % (95 % CI 89.0-98.6 %). 
Specificity was calculated to be 98 % (95 % CI 93.6-99.5 %) (Table 6). These values 
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indicated good performance for the designed PCR and microarray assay. Similar results 
were introduced also by Wiesinger-Mayr and co-workers (2007) with a comparable 
method, achieving 100 % specificity on the genus level and 97 % on the species level 
using reference strains and clinical isolates. 
 
In conclusion, proof-of-concept was successfully demonstrated for the PCR and 
microarray assay. However, the bacterial panel of the assay was somewhat limited and 
did not cover all important sepsis causing organisms such as P. aeruginosa and relevant 
species from the Enterobacteriaceae group including E. coli (Beekman et al., 2003; 
Schmitz and Lehmann, 2011) Thus, an optimal assay with an optimized oligonucleotide 
probe panel and carefully selected analysis algorithms would increase suitability of the 
assay for diagnostic use and obviate any manual result interpretation or post hoc 
adjustment. 
 
4.1.3 Extension of target panel and clinical validation of the assay (II) 
In order to improve the target panel of the evaluated end-point PCR and microarray assay, 
new oligonucleotide probes were designed for the detection of over 50 relevant Gram-
negative and Gram-positive bacterial species, 24 on species and 26 on taxon level (Table 
5). The hybridization protocol was also optimized to be more rapid, easier to use and 
suitable for the new probe content. The improved assay was clinically validated in two 
hospitals in Europe, in HUSLAB, Finland and UCLH, London. A set of 3318 blood 
culture samples were collected in these two laboratories during 2008. Samples were 
analyzed simultaneously by the improved PCR and microarray assay (named Prove-it™ 
Sepsis) and conventional culturing method in both laboratories. The validation study is 
presented in detail in the original publication II. Five samples were excluded from the 
sample set due to sampling error and 29 samples due to operator or technical error. In 
total, 3284 samples were included in the analysis, of which 2107 were blood culture 
positive and 1211 blood culture negative samples. Of all the blood culture positive 
samples, 86 % contained a pathogen covered by the target panel of the Prove-it™ Sepsis 
assay. The most frequently identified bacteria were E. coli, S. aureus, S. epidermidis, S. 
pneumoniae and K. pneumoniae all of which are also reported as causative organisms in 
many sepsis related studies (Vincent et al., 2006; Harbarth et al., 2003). The assay panel 
did not cover organisms such as Streptococcus viridans or Candida spp. and 1,1 % of 
Staphylococcus sp. found in this study was not covered by the CNS panel of the assay 
(Publication II: Table 3). These represent obvious areas of improvement to be included in 
the assay later. Especially, rapid identification of different Candida spp. would allow 
earlier administration of antifungal therapy since for example in the UK the prevalence of 
fungemia is three to five cases per 100 000 populations (Odds et al., 2007). 
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Table 5. Target panel of the improved PCR and microarray assay (Prove-it™ Sepsis 
assay) 
Gram - 
 
Gram + 
      
Acinetobacter baumannii   mecA methicillin resistance marker 
Enterobacter aerogenes     
Enterobacter cloacae   Clostridium perfringens 
Escherichia coli   Enterococcus faecalis 
Haemophilus inuenzae   Enterococcus faecium 
Klebsiella oxytoca   Listeria monocytogenes 
Klebsiella pneumoniae   Staphylococcus aureus 
Neisseria meningitidis   Staphylococcus epidermidis 
Proteus mirabilis   Streptococcus agalactiae 
Proteus vulgaris   Streptococcus dysgalactiae 
Pseudomonas aeruginosa   ssp. equisimilis 
Salmonella enterica ssp. enterica   Streptococcus pneumoniae 
Serratia marcescens   Streptococcus pyogenes 
Stenotrophomonas maltophilia     
      
Bacteroides fragilis group   Coagulase negative Staphylococcus 
Campylobacter jejuni/coli     
Enterobacteriaceae     
      
Neisseria sp. non-meningitidis     
Bacteroides fragilis detects at least the following species: B. fragilis, B. vulgatus,  
B. thetaiotaomicron. 
Coagulase negative Staphylococcus detects at least the following species: 
S. haemolyticus, S. hominis, S. lugdunensis, S. saprophyticus, S. warneri, S. xylosus. 
Enterobacteriaceae detects at least the following species: Citrobacter amalonaticus, 
Citrobacter braakii, Citrobacter freundii, Citrobacter koseri, Enterobacter hormaechei, 
Enterobacter sakazakii, Kluyvera intermedia, Morganella morganii, Pantoea agglomerans, 
Providencia rettgeri, Providencia stuartii, Yersinia enterocolitica, Yersinia pseudotuberculosis. 
Neisseria sp., non-meningitidis covers at least the following species: N. gonorrhoeae, N. 
subflava, N. sicca, N. cinerea, N. elongata subspecies nitroreducens, N. flavescens,  
N. lactamica. 
Salmonella enterica subspecies enterica detects at least the following serovars: Enteritidis, 
Oranienburg, Othmarschen, Panama, Paratyphi, Stanley, Typhi, Typhimurium, Virchow, 
group A,B,C,D. 
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Identification results by the Prove-it™ Sepsis assay were compared to the culturing. 
Based on these results, 18 false positive and 94 false negative samples were reported by 
PCR and microarray assay (Publication II: Table 5). Over half of the false positive 
findings (11 out of 18) related to polybacterial finding such as identification of an 
additional CNS from the seven samples, most probably due to skin contamination in the 
sample (Richter et al., 2002; Hall and Lyman, 2006). Other false positive findings were 
cross-hybridizations or caused by undetermined reasons. Most of the false negative 
findings related to limitations in the sensitivity of the assay (23 samples) or incorrectness 
in a polybacterial identifications (60 samples). In addition, six false negative samples 
(five E. coli and one K. pneumoniae) were identified only on the taxon level instead of 
species level and only mecA was detected from five samples without Staphylococcus 
species identification (Publication II: Table 5). However, the amount of false positive and 
false negative samples was relatively small (112 samples) from the set of 3284 samples. 
Based on these results, 94.7 % (95 % CI 93.6-95.7 %) sensitivity and 98.8 % (95 % CI 
98.1-99.2 %) specificity was obtained according to the CLSI guidelines (2002) for the 
assay. These values were similar to the values of the performance evaluation study 
demonstrating that the extension of the target panel did not negatively affect the 
sensitivity or specificity of the assay (Table 6). The results were also comparable to 
published values of other assays for pathogen identification from positive blood culture 
samples in case of sepsis and BSI. Tormo and co-workers (2012) demonstrated 98.5 % 
sensitivity and 100 % specificity for Verigene
®
 Gram-positive assay (Nanosphere Inc, 
USA) with 65 samples. Comparing the concordance of results with reference methods 
(Publication II: Table 2), Kaleta and co-workers (2011) published similar species level 
and genus level concordances; 95.6 % and 96.7 %, respectively, for PCR-ESI MS (Abbott 
Ibis Bioscience, USA) and 94.9 % and 97.1 %, respectively, for MALDI-TOF MS 
(Bruker, Germany). 
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Table 6. Sensitivity and specificity of the improved PCR and microarray assay calculated 
based on the performance evaluation study (Publication I) and clinical validation 
study (Publication II) according to CLSI guidelines (2002), when conventional 
blood culturing was used as the reference method. 
  
Positive identification 
by the PCR and 
microarray assay 
Negative identification 
by the PCR and 
microarray assay 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Performance evaluation study (n = 186) (Publication I)     
Positive by 
reference method 
73 true positive 3 false negative 
96 % 
a 
                 
(89.0-98.6) 
  
Positive/negative 
by reference 
method 
b
 
2 false positive 108 true negative   
98 %                     
(93.6-99.5) 
Clinical validation study (n = 3284) (Publication II)     
Positive by 
reference method 
1696 true positive 94 false negative 
94,7 %                   
(93.6-95.7) 
  
Positive/negative 
by reference 
method 
b
 
18 false positive 1476 true negative   
98,8 %                 
(98.1-99.2) 
 
a
 Initial sensitivity of 82 % was calculated without described result interpretation adjustment 
 
b
 Blood culture positive samples, including pathogens not covered by the assay  
CI = confidential intervals       
 
 
The validation study showed that the developed Prove-it™ Sepsis assay can be used for 
sepsis diagnostics and the assay achieved CE-IVD approval. The target identification 
result could be obtained during the same working day when the blood culture has turned 
positive. These results indicate that the assay meets the requirements of rapid diagnostics 
which could improve patient outcome by offering early identification results for targeted 
antimicrobial therapy (Harbarth et al., 2003).   
 
4.1.4 PCR and microarray assay: transfer from tube to strip platform (III) 
The amounts of blood culture samples in hospital laboratories are dependent on the size 
of the hospital. A diagnostic assay directed to sepsis and BSI should cover the 
functionality and throughput needs of both small and large hospital laboratories. In order 
to meet these requirements, the end-point PCR and microarray assay was first developed 
using a single tube array platform (Prove-it™ TubeArray) allowing batching of 1-24 
samples (Publications I and II). The performance of this assay was successfully 
demonstrated (Table 6) with patient samples. The same oligonucleotide content was then 
transferred onto a higher-throughput platform (Prove-it™ StripArray, Publications III and 
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IV). The strip array contains eight reaction wells on a strip with a low-density microarray 
at the bottom of each well and allows batching of 1-96 samples. A specific reader was 
used for automatic imaging and analysis of strip arrays without manual steps (Figure 2 
and 3). The reader consists of an integrated camera, a visible light source and the Prove-
it™ Advisor analysis software. Similar built-in analysis rules were used for species and 
taxon level identification of target organisms than for analysis of tube arrays. The end-
point PCR producing ssDNA was the same for both used microarray platforms, but the 
colorimetric hybridization protocol was optimized for these microarray platforms 
separately. 
  
 
Figure 2 Microarray platform including low-density microarrays with oligonucleotide probes 
at the bottom of eight-well strips (Prove-it™ StripArray) and a specific colorimetric 
reader for detection of hybridization reactions from the microarray. Identification of 
targets is based on built-in analysis rules and results are reported by the analysis 
software (Prove-it™ Advisor). 
91 positive blood cultures were freshly collected in HUSLAB, Finland (Publication III) 
for performance evaluation of the Prove-it™ Sepsis assays in strip array platform. DNA 
of the samples was extracted as duplicates with NucliSENS
® 
easyMAG
®
 (bioMérieux, 
France) and NorDiag Arrow (NorDiag, Norway) devices and analyzed with the 
microarray assay. Simultaneously, conventional blood culturing was performed in 
HUSLAB according to the CLSI guidelines (2007; 2011). Results showed that 96.7 % 
(88/91 samples) of the samples were correctly identified by the developed assay. 
Identified bacteria (E. coli, S. aureus and other Staphylococcus spp., K. pneumoniae and 
E. faecalis) represented typical pathogens found in sepsis and BSI cases (Vincent et al., 
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2006). When the bacterial identification results were initially compared to the results of 
conventional method, 12 discrepant results were found (Publication III: Table 2) of which 
nine were later confirmed to be correct identifications by the PCR and microarray assay. 
From those nine samples, the microarray assay correctly identified for example S. 
pneumoniae in two samples which remained negative by culturing, Streptococcus 
dysgalactiae subsp. equisimilis in two samples which were identified as S. pyogenes by 
culturing and S. epidermidis in two samples when only taxon level identification was 
achieved by culturing. The PCR and microarray assay provided incorrect results in three 
cases: one multi-infection sample was marked as false negative due to missing 
identification of E. faecium, one sample was false positive due to a contamination of E. 
faecalis in that test series and one sample resulted in identification of S. aureus with CNS, 
while culturing reported only Staphylococcus capitis.    
 
These results with only few discrepant identifications demonstrated that the Prove-it™ 
Sepsis assay on the strip array platform offered similar performance as the tube array 
platform. Many studies report that high-throughput; labor-efficient automated analysis 
could be standardized and could offer faster results (Reguiro et al., 2010). Simultaneous 
analysis of 1 - 96 microarrays with the automated reader and software offers rapid results 
without result interpretations by user. 
4.2 Development of identification of Staphylococcus spp. on 
microarray 
4.2.1 Design and validation of Staphylococcus aureus and mecA detection 
(I,II,IV) 
S. aureus is responsible for a substantial amount of bloodstream infections and therefore 
emphasis was put on sensitive identification of the target with the PCR and microarray 
assay. In addition to the broad-range primers, the multiplex PCR used in the assay 
contained specific primers for mecA gene and S. aureus for enhancing the amplification 
of the target. A set of oligonucleotide probes targeted to S. aureus and mecA were 
designed and printed on the microarray. The performance of detection of S. aureus or 
S.aureus with mecA in case of MRSA was evaluated with clinical isolates and the blood 
culture samples presented in publication I. Comparison of the assay results with culturing 
results showed correct identification of S. aureus from MSSA strains and S. aureus with 
mecA from MRSA strains with two discrepancies. In total, S. aureus was correctly 
detected from 24 blood culture samples (Publication I: Table 4). One sample remained 
false negative due to an unverified reason, most probably due to degraded DNA or PCR 
inhibitors present in the sample. The other false negative sample was marked as positive 
after post hoc adjustment of identification parameters.  
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The performance of identification of S. aureus and mecA was further improved by design 
revision after publication I and clinically validated with blood culture samples during the 
clinical validation of the Prove-it™ Sepsis assay presented in publication II. S. aureus 
was detected from 201 of 209 monobacterial samples (96.2 %) and S. aureus with mecA 
indicating MRSA (Figure 3) was detected from 16 samples showing 100 % concordance 
with reference results (Publication II: Table 2). Of the eight discrepancies, one sample 
was false negative due to inadequate sensitivity of S. aureus detection by the assay. Seven 
samples were reported as false positive because CNS was reported together with S. 
aureus instead of S. aureus alone. These results were most probably due to skin 
contamination (Hall and Lyman, 2006). The PCR and microarray assay also failed to 
identify S. aureus from nine multibacterial samples. The performance of detection of S. 
aureus and mecA by the PCR and microarray assay was comparable to other commercial 
assays developed for detection of S. aureus and MRSA from blood cultures. Stamper and 
co-workers (2007) evaluated BD GeneOhm (Franklin Lakes, USA) test for positive blood 
culture samples and obtained 98.9 % sensitivity and 96.7 % specificity for MRSA. 
 
MRSA contains a highly mobile element SCCmec which carries the mecA gene, the 
causal factor of methicillin-resistance (Peng et al., 2010; Shore et al., 2011). Different 
SCCmec elements have been identified and therefore the PCR and microarray assay on 
the strip array platform was tested with important epidemic MRSA clones (Publication 
IV: Table 1). 18 MRSA clones carrying SSCmec types I, II, IV, V or a non-typable 
SSCmec (containing ccrA1, ccrA2 and class B type of mec) were tested with in 
concentrations (10
5 
and 10
3 
GE) as duplicates. The results showed that the PCR and 
microarray assay successfully detected S. aureus and mecA from each MRSA clone.  
 
The results demonstrated that the developed PCR and microarray assay detected one of 
the most prevalent sepsis and BSI causing bacterium S. aureus from patient samples with 
high accuracy. The detection of multibacterial samples could still improve. However, 100 
% identification of MRSA from blood culture samples and detection of clinically relevant 
MRSA clones showed that assay is usable for accurate identification of S. aureus with 
mecA resistance marker. Simultaneous detection of resistance markers together with 
causative bacterial species may shorten the time to effective antimicrobial therapy, 
especially in the case of MRSA which is associated with high mortality and morbidity 
(Louie et al., 2002; Harbarth et al., 2003). 
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Figure 3 Analysis report generated by the Prove-it™ Advisor analysis software. The result 
table indicates the amount of printed and detected oligonucleotides and highlights 
successful identification of S.aureus and mecA from the sample. The software takes 
an image from the bottom of the tube, crops the microarray image and analyses it, 
indicating different detected oligos by colors. Colorimetric positive hybridization is 
visualized by black spots on the microarray. Yellow marked spots are target specific 
oligos and green marked spots are control oligos. 
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4.2.2 Design and validation of Coagulase-negative Staphylococcus 
detection (I, II) 
The PCR and microarray assay was developed to identify S. epidermidis on species level 
and other relevant CNS species on taxon level. The performance of S. epidermidis and 
CNS identification by the PCR and microarray assay was evaluated with clinical isolates 
and blood culture samples, presented in publication I.  S. epidermidis was successfully 
detected from eight blood culture samples. One sample was left false negative, but also 
16S rDNA confirmatory PCR was negative indicating the presence of PCR inhibitors or 
degraded DNA in that sample. One sample was negative due to low quality of the probes 
and that sample was marked to be positive after adjustment of the built-in analysis rules 
of the analysis software.  
 
The performance of S. epidermidis detection was further improved by design revision 
after publication I and clinically validated in the Prove-it™ Sepsis assay with blood 
culture samples presented in publication II. 246 monobacterial S. epidermidis findings 
were obtained by culturing and 240 (97.6 %) of those were detected by the Prove-it™ 
Sepsis assay. The PCR and microarray assay failed to identify S. epidermidis from ten 
multibacterial samples (Publication II: Table 5). According to Piette and co-workers 
(2006), over 50 % of the CNS isolates found from clinical samples are S. epidermidis. 
These bacteria are also reported to cause neonatal sepsis infections posing significant 
burden to public healthcare especially when carrying resistance genes (Cheung and Otto, 
2010). The results demonstrated successful identification of S. epidermidis especially 
from monobacterial samples by the designed PCR and microarray assay. 
 
The CNS panel of the PCR and microarray assay was proven to detect prevalent 
Staphylococcus haemolyticus, Staphylococcus saprophyticus and Staphylococcus xylosus, 
and also the highly virulent Staphylococcus lugdunensis (Publication I: Table. 2) clinical 
isolates. When blood culture samples were tested, S. haemolyticus was identified as CNS 
from two samples, while six other samples remained negative containing CNS species 
such as Staphylococcus pasteuri, S. capitis and Staphylococcus hominis not included in 
the target panel of the microarray assay. Therefore the assay coverage was extended to 
detect also S. capitis, S. hominis and Staphylococcus warneri in the CNS group. The 
functionality of this extension was clinically validated with blood culture samples of 
publication II. CNS was detected from 165 samples by culturing and the CNS panel of the 
PCR and microarray assay covered 133 of those. Correct identification was achieved from 
123 monobacterial samples yielding 92.5 % concordance for CNS detection by the Prove-
it™ Sepsis assay when compared to culturing results. The role of CNS as pathogens and 
their increasing incidence as causative bacteria in infections has been recognized (Piette 
and Verschraegen, 2009). The results demonstrated accurate identification of important 
CNS species at the taxon level by the PCR and microarray assay.  
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4.3 Accurate DNA-based detection compared to culturing and 
phenotype-based characterization of bacteria (II, III) 
DNA-based characterization of bacteria has opened a new era in bacterial taxonomy and 
opportunities to detect non-viable pathogens from samples where conventional methods 
may fail (Mancini et al., 2010; Soraya et al., 2008; Klouche and Schröder, 2008). During 
the presented PCR and microarray development and evaluation study, results revealed 
examples where DNA-based identification offered more accurate bacterial identification 
than phenotypic characterization from positive blood culture samples. S. pneumoniae was 
identified from five samples by the PCR and microarray assay when culturing reported 
negative results most probably because of the autolysis of microbes or the slow growth of 
bacteria (Publications II and III). S. pneumoniae may experience autolysis when 
stationary growth section is achieved and therefore conventional culturing may fail 
(Martner et al., 2009). Gram-staining supported S. pneumoniae findings and they were 
also confirmed by sequencing the gyrB gene region. Correct identification is important 
since considerable morbidity and mortality are associated especially to neonatal sepsis 
when S. pneumoniae is the causative agent (Hoffman et al., 2003).  
   
Culturing method reported S. pyogenes from two samples when the PCR and microarray 
assay identified S. dysgalactiae subsp. equisimilis (Publication III: Table 2). The 
bacterium was confirmed to be S. dysgalactiae subsp. equisimilis by sequencing the gyrB 
gene region in both cases. Streptococci are classified based on their Lancefield group 
antigens and species identification generally utilizes serotyping of streptococci. S. 
dysgalactiae subsp. equisimilis may express Lancefield's serogroup C or G, and S. 
pyogenes almost exclusively expresses serogroup A. Brandt and co-workers (1999) 
investigated blood culture isolates and found similar results where Lancefield's serogroup 
A was detected from S. dysgalactiae subsp. equisimilis. They concluded that this kind of 
S. dysgalactiae subsp. equisimilis is probably as pathogenic as those exhibiting 
Lancefield’s serogroup C or G antigen and other methods than serotyping should be used 
for species identification (Brandt et al., 1999). 
 
The PCR and microarray assay identified Enterobacteriaceae group from seven blood 
culture samples while culturing reported E. coli (Publications II and III). The sequencing 
of the gyrB gene region showed nucleotide variations and only 96 – 98 % homology to 
that of E. coli sequence. gyrB gene regions from Escherichia fergusonii and Escherichia 
hermannii were also sequenced since they are closely related species of E. coli and can be 
misidentified as E. coli (York et al., 2000). The sequence comparison showed that the 
obtained sequences were not 100 % similar to the gyrB gene regions of E. fergusonii and 
E. hermannii sequences or other sequences found from public sequence databases. In 
conclusion, the isolates could belong to Escherichia genus but were not E. coli. These 
results were taxonomically interesting but the clinical significance in these cases would 
be low. 
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4.4 Comparison of DNA extraction methods (III) 
The developed Prove-it™ Sepsis PCR and microarray assay was aimed at the 
identification of sepsis causing bacteria from blood culture samples. Blood culture is a 
complicated sample matrix, and therefore effort must focus on examining the cell wall 
disruption of microbes and recovery of microbial DNA without putative PCR inhibitors 
from different DNA extraction methods. NucliSENS
®
easyMAG
®
 (bioMérieux, France) 
extraction device was used as the extraction system when the developed PCR and 
microarray assay was validated with patient samples (Publication II). This extraction 
system is typically classified as the gold standard method, when different extraction kits 
are compared. The device has been demonstrated to be efficient, but the reagent costs are 
not cheap and the original device investment may be high (Dundas et al., 2008). 
Therefore the performance of the alternative extraction device NorDiag Arrow (Nordiag, 
Norway) and Viral NA kit was evaluated. The DNA from a set of 91 positive blood 
cultures was extracted simultaneously with both devices and samples were analyzed by 
the Prove-it™ Sepsis assay. The bacterial identification results from DNA extracts 
isolated with both devices showed 100 % concordance (Publication III: Table 1). Both 
systems successfully lysed and extracted Gram-negative and Gram-positive bacteria from 
blood culture samples. The amount of Gram-positive bacteria was 35.2 % of all the tested 
samples and contained species such as Staphylococcus spp. and Streptococcus spp. whose 
rigid cell wall is typically difficult to lyse (Sohail, 1998). 
 
In addition, dilution series from E. coli clinical isolate was used for DNA extraction 
simultaneously with both devices to examine DNA yields and purity with a 
spectrophotometer and real-time PCR using the dxs gene region for amplification. Three 
parallel samples were isolated per each concentration in the dilution series with both 
devices and in general, the performance had only little variation. Standard deviation was 
high with the NorDiag Arrow device when concentration and purity from parallel DNA 
samples was compared with NucliSENS
®
easyMAG
®
. Variation was not obtained in 
standard deviation from parallel DNA samples extracted with NucliSENS
®
easyMAG
®
, 
indicating more consistent extraction quality and reproducibility (Publication III: Fig. 1 
and Fig. 2). However, none of the isolated samples achieved the eligible purity value of 
1.8 A260/280. It is noteworthy that the ability of the spectrophotometer to measure low 
concentrations is a limitation of the method. The measurements out of optimal purity 
range of DNA (i.e. A260/280 -ratios of 1.5-2.0) may also cause some variation in the results 
(Kim et al., 2008). The results showed some variation in the quality and reproducibility 
between NucliSENS
®
easyMAG
®
 and NorDiag Arrow and if these devices are used for 
other purposes, more precise investigation would be recommended. The results of this 
study demonstrated that both devices can be used for extraction of DNA from blood 
culture samples when the Prove-it™ Sepsis assay is used for analysis of the DNA 
extracts. 
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4.5 Application for whole blood sample type (IV) 
Assays for sepsis diagnostics usually use blood culture or whole blood as sample type. 
The developed PCR and microarray assay (Prove-it™ Sepsis) was demonstrated to be a 
sensitive detection method of bacteria from blood culture (Publications I-III). Whole 
blood is a more complicated sample material since the amount of infecting bacteria in 
clinically significant  bacteremia may be low and levels of substances potentially 
interfering with analysis are high (Al-Sould et al., 2000; Ecker et al., 2010). The 
suitability of the PCR and microarray assay for identification of pathogens without a 
blood culturing step was investigated by combining a specific DNA extraction method 
with analysis by the PCR and microarray assay. 
 
An almost similar PCR and microarray assay using the strip array platform as described 
in original publication III was slightly modified for analysis of whole blood samples. The 
assay (named Prove-it™ Bone & Joint) was originally aimed at the detection of bone and 
joint infection causing pathogens from clinical specimens including osteoarticular fluids 
and bone biopsies (Metso et al., 2013).  These sample types contain low amounts of 
bacteria and high levels of inhibitors similar to the whole blood sample type. The sample 
volume per PCR reaction and amount of amplicons for hybridization was increased to 
enhance assay sensitivity. The hybridization protocol was also optimized to allow a 
highly sensitive detection with these modifications. The assay was combined together 
with the commercially available Blood pathogen DNA isolation kit (Molzym, Germany), 
which is used on the automated NorDiag Arrow (NorDiag, Norway) extraction device 
(Publication IV: Fig. 1). This specific bacterial DNA extraction method selectively 
concentrates bacterial cells and degraded human DNA followed by the extraction of 
bacterial DNA from one mL of whole blood sample. 
 
The combination assay was evaluated by spiking whole blood with a dilution series of 
bacteria prevalent in sepsis. DNA of spiked samples was extracted as duplicates with the 
described method and DNA extracts were analyzed by the described PCR and microarray 
assay. The detection limits for the combined solution were determined to be the lowest 
amount of CFUs in the blood sample yielding to a correct bacterial identification by the 
PCR and microarray assay from one or both duplicates. The obtained limit-of-detection 
(LOD) values were 11 CFU/mL for E. coli, 13 CFU/mL for E. faecalis, 68 CFU/mL for 
K. pneumoniae, 86 CFU/mL for MRSA (combined detection of S. aureus and mecA), 250 
CFU/mL for L. monocytogenes, and 600 CFU/mL for S. agalactiae (Publication IV: 
Table 3). Lehmann and co-workers (2007) introduced detection limits of 3 CFU/mL - 100 
CFU/mL depending on the bacterial species with the LightCycler
®
 SeptiFast Test 
MGRADE assay, which is the best-established solution for whole blood. The results with 
spiked whole blood samples demonstrated that the sensitivity of the combined assay was 
on the same level for most of the tested bacteria. However, with some targets (i.e. L. 
monocytogenes and S. agalactiae) the assay did not achieve the same sensitivity levels.  
 
  
 
 
51 
To evaluate the dissipation of bacterial DNA during sample preparation steps, DNA from 
similar clinical isolates which were used for blood spiking, were diluted and tested as 
duplicates by the modified PCR and microarray assay. Analytical sensitivity was 
determined to be the lowest amount of GE in the PCR reaction which led to a successful 
bacterial identification from at least one of the tested duplicates. Detection limits for the 
PCR and microarray assay were 1 GE for E. coli, 8 GE for K. pneumoniae, 11 GE for S. 
aureus, 15 GE for E. faecalis, 16 GE for L. monocytogenes, 17 GE for MRSA (combined 
detection of S. aureus and mecA), and 21 GE for S. agalactiae (Publication IV: Table 2). 
These results showed that only few genome copies were sufficient for production of an 
adequate amount of amplicons for detection on the microarray. Analytical sensitivity 
values were compared to the detection limits obtained with the combined assay with 
spiked whole blood samples, although one must note that CFU/mL and GE are not totally 
comparable units. The results indicated possible PCR inhibitor residues from blood and/or 
losses of bacterial DNA during the sample preparation step.  
 
In conclusion, sensitivities for some of the bacteria reached a suitable level of 1-30 
CFU/mL, values which are typically obtained from whole blood in sepsis (Ecker et al., 
2010). Mühl and co-workers (2011) indicated with a similar extraction method that the 
total amount of positively detected samples by PCR method raised from 50 % to 79 % 
when sample volume was increased from 1 mL to 5 mL. Similar improvement could also 
positively affect the sensitivity values obtained in this study. The results demonstrated 
proof-of-concept for this combination of a specific DNA extraction method with the PCR 
and microarray analysis assay. Full understanding of the sensitivity and reproducibility of 
the assay should still be further investigated with a broader bacterial panel as well as with 
real patient samples.  
 
4.6 User requirements for a diagnostic assay of sepsis (II, III, IV) 
Afshari and co-workers (2012) listed several commercially available assays with different 
detection strategies which have been developed for faster sepsis and BSI diagnostics. 
New assays need to follow the territorial regulations before they can be offered for 
diagnostic use. Introducing an assay to the EU market requires CE marking for in vitro 
diagnostic (IVD). Also FDA sets similar requirements for products introduced in US 
markets (Directive 98/79/EC, 1998; Kimmelman, 2003). In this study, the Prove-it™ 
Sepsis PCR and microarray assay with tube and strip platform were developed in 
compliance with the Directive 98/79/EC and therefore attained the CE-IVD marking. 
They are commercially available in Europe.  
 
High mortality and the reported six hour time window during which the risk for death in 
septic patient’s increases substantially sets high requirements for rapid identification of 
causative pathogens. Inappropriate patient treatment has been shown to result in poor 
patient outcomes and an increase hospital costs (Harbarth et al., 2003; Kumar et al., 
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2006). During the study presented in the original publication II, the turnaround times for 
identification of bacterial species from blood culture by the Prove-it™ Sepsis assay were 
compared with conventional culturing using a randomly chosen set of 39 samples. The 
result showed that the median time difference was 18 hours 19 minutes and in general, the 
results with the Prove-it™ Sepsis assay were achieved during the same day when blood 
culture turned positive. This indicated faster results for clinicians for review of patient 
management. The PCR and microarray assay was also combined with a specific DNA 
extraction method and the sensitivity of this solution was demonstrated to be on a suitable 
level for pathogen identification from spiked whole blood samples. This combination 
offers faster identification results than analysis from positive blood culture samples. 
However, the study was only a proof-of-concept and the solution needs further 
development and evaluation. 
 
Many studies conclude that faster results can be achieved by automating previously 
manual steps. Automation could offer labor-efficient, standardize results between 
different users and can reduce human errors (Reguiro et al., 2010). Depending on samples 
and size of the laboratory, a high-throughput platform can speed up diagnostics, when 
several samples from the same patient as well as increased number of patients can be 
tested simultaneously. These user requirements were also taken into consideration when 
the diagnostic PCR and microarray assays were developed in this study. The Prove-it™ 
Sepsis assay was developed for two platforms, the tube and strip array format. The tube 
array format allowed analysis of 1-24 samples and the higher-throughput strip array 
format allowed analysis of 1-96 samples simultaneously. The hybridization protocols for 
both tube and strip format are still manual and require manual pipetting. The analysis 
software (Prove-it™ Advisor) was developed to be instinctive and produce analysis 
results automatically without the need for result interpretation by user (Figure 3). 
Analysis of results on the strip array format was a wizard-guided automated protocol 
capable of providing identification results from 96 samples in one run without user 
intervention after each sample. The level of automation was also increased by using DNA 
extraction devices together with the developed PCR and microarray assay. Automated 
NucliSENS
®
easyMAG
®
 and NorDiag Arrow devices were evaluated with blood culture 
samples and the semi-automated specific extraction kit combined with the NorDiag 
Arrow device was tested with spiked whole blood samples. 
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5 Conclusion and Future prospects 
Sepsis, severe sepsis and septic shock are associated with high mortality rates and it is 
estimated that around 1400 patients die for severe sepsis every day (Ebrahim, 2011; 
Daniels, 2011). Patients with severe sepsis stay approximately 19.6 days in hospital in the 
US and related costs are estimated to rise to $16.7 billion annually (Angus et al., 2001). 
These numbers illustrate the difficulty of treating seriously ill septic patients. Kumar and 
co-workers (2006) demonstrated that every additional hour during the first six hours from 
hypotension onset without appropriate antimicrobial treatment increases the risk of death 
by 7.6 % in septic patients. Other studies have also demonstrated lower mortality rates 
among adequately treated patients (Harbarth et al., 2003; Bochud et al., 2004). 
 
Sepsis diagnostics needs faster assays, which can offer reliable pathogen identification 
and resistance screening. The aim of this study was to develop a PCR and microarray 
assay for rapid detection of pathogens and resistance markers from blood culture samples. 
The proof-of-concept of the assay was established in publication I. The bacterial panel of 
the assay was extended to cover over 50 relevant or resistant species which may change 
antimicrobial treatment when detected from the sample. Targeted patient management 
based on the identified causative pathogen may result in better patient outcomes and save 
lives. This improved assay was successfully validated in publication II. The study focused 
also on modifying the assay to be suitable and easily implementable to small as well as 
large hospital laboratories. The amount of samples varies significantly between 
laboratories and thus the developed PCR and microarray assay was optimized for both the 
tube array platform and the higher-throughput strip array platform capable of identifying 
1 - 96 samples simultaneously (Publication III).  
 
The amount of NA-based methods for the identification of causative pathogens from 
patients with suspected sepsis has increased substantially during the past ten years. In 
1997, Reimer and co-workers (1997) concluded that no NA-based identification methods 
are available for routine use, but lots of research is ongoing in the area. Nowadays, 
several publications are introducing tens of commercially available NA-based assays, 
which aim are to improve and offer tools for rapid and accurate diagnostics and decrease 
the mortality rate of septic patients (Afshari et al., 2012; Paolucci et al., 2010; Dark et al., 
2009). The developed PCR and microarray assay (Prove-it™ Sepsis) with both tube and 
strip array platform received CE-IVD marks and are among those NA-based 
commercially available assays in Europe. The broad-range primer design and microarray 
platform of this PCR and microarray assay offers robust and flexible combination where 
identification of new targets can be easily implemented. Thus, the scope of the Prove-it™ 
Sepsis assay has already improved after this study with the addition of twelve Candida 
species together with additional bacterial targets (Aittakorpi et al., 2012).  
 
Simultaneous evaluation of bacterial resistances provides earlier information than 
conventional susceptibility testing and may decrease the time to targeted treatment. 
Validation of the developed PCR and microarray assay in publication II demonstrated 100 
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% sensitivity and specificity for identification of S. aureus and mecA from MRSA 
samples. In addition, the capacity of this assay to detect epidemiologically important 
MRSA clones was successfully shown in publication IV. The antimicrobial resistance 
panel of the Prove-it™ Sepsis assay has already been extended after the present study to 
detect also vancomycin resistance markers and the addition of other gene markers such as 
fluoroquinolone resistance markers or other markers related to Gram-negative bacteria 
can be considered in the future. 
 
Novel assays developed for rapid sepsis diagnostics follow two different strategies based 
on the sample type. Assays which use blood culture as the sample type offer comparable 
identification results with gold standard methods. Results are typically achieved faster 
than with the conventional method, but culturing of pathogens in blood culture bottles is 
still time-consuming. Whole blood as the sample type offers time advantage when 
culturing is avoided. However, the achieved results and the significance of pathogen 
DNA as a marker in infection are still under discussion, since viable bacteria are not 
required for positive detection. Also the lack of reference methods from whole blood at 
the moment increases problems to interpret the results. 
 
In this study, a PCR and microarray assay was developed for blood culture sample type 
since it can be easily implemented in routine laboratories (Publications I-III). In addition, 
the suitability of the assay to achieve adequate sensitivities required for whole blood was 
also tested (Publication IV). Since sample preparation is a highly critical step, a specific 
bacterial DNA extraction method was used together with the PCR and microarray assay. 
The results demonstrated good proof-of-concept and also the potential of the assay to be 
used directly for other non-enriched sample types such as tissue and different body fluids. 
The PCR and microarray assay is already used as a research method for pathogen 
identification from laryngitis and nasal lavage samples not related to sepsis and can be 
consider also for other applications (Kinnari et al., 2012, Allen et al., 2013). 
 
In conclusion, sepsis is a serious infection and its diagnosis is not unambiguous. Initial 
empirical treatment of a septic patient is typically a combination therapy. Targeted 
antimicrobial therapy can be started immediately after the causative pathogen has been 
identified. Many molecular and protein-based assays have been developed next to the 
current culturing-based gold standard method in an attempt to reduce mortality, evolution 
and spread of bacterial resistance, toxicity and costs. None of those assays have yet 
replaced the current culturing method but are valuable tools, especially when used for 
certain groups of patients under higher risk. New assays have faced criticism especially 
for their high costs, since traditional culturing is relatively cheap and some of the new 
tests may require expensive device and reagent investments. However, every additional 
day in hospital causes major costs and thus faster methods which can produce pathogen 
identification and susceptibility results earlier, can decrease the length of stay in hospital.  
 
NA-based assays have already opened a new era and brought broadened perspective to 
microbiological laboratories beside conventional culturing methods. Understanding the 
  
 
 
55 
clinical relevance of DNAemia/circulating DNA may open new strategies for septic 
patient management. New attempts for development of point-of-care tests for sepsis 
diagnostics are increasingly reported. Their protocols of sample in – results out allow fast 
analysis without manual steps and special skills of the user. This progressing development 
of new techniques and assays is a trend, which is predicted to spread to all fields in 
clinical microbiology in the future. Hopefully, these assays can be used for improved 
patient management worldwide including developing countries. 
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